CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | anilide |
|
Accession: | CHEBI:13248
|
browse the term
|
Definition: | Any aromatic amide obtained by acylation of aniline. |
Synonyms: | related_synonym: | Formula=C7H6NOR; N-phenyl amide; N-phenyl amides; SMILES=[*]C(=O)Nc1ccccc1; an anilide |
| xref: | KEGG:C01402; PMID:23535982; PMID:23968552; PMID:24273122; PMID:6205897 |
|
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
3,3',4',5-tetrachlorosalicylanilide results in increased expression of ATF3 mRNA |
CTD |
PMID:27965148 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
increases expression |
ISO |
3,3',4',5-tetrachlorosalicylanilide results in increased expression of DNAJB4 mRNA |
CTD |
PMID:27965148 |
|
NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089
|
|
G |
Iyd |
iodotyrosine deiodinase |
multiple interactions |
ISO |
3,3',4',5-tetrachlorosalicylanilide inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
3,3',4',5-tetrachlorosalicylanilide inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases activity multiple interactions |
ISO |
acetochlor results in increased activity of ABCB1 protein ABCB1 protein affects the reaction [acetochlor results in increased susceptibility to Paclitaxel] |
CTD |
PMID:18433974 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases export |
ISO |
ABCC1 protein results in increased export of acetochlor metabolite |
CTD |
PMID:18433974 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Aplf |
aprataxin and PNKP like factor |
affects response to substance |
ISO |
APLF gene SNP affects the susceptibility to acetochlor |
CTD |
PMID:25622337 |
|
NCBI chr 4:120,070,471...120,122,656
Ensembl chr 4:120,070,471...120,122,633
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
acetochlor inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein] |
CTD |
PMID:33049310 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
ISO |
acetochlor results in increased expression of BAD protein |
CTD |
PMID:25291404 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases expression |
ISO |
acetochlor results in increased expression of BAK1 protein |
CTD |
PMID:25291404 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
acetochlor results in increased expression of BAX protein |
CTD |
PMID:25291404 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
affects expression |
ISO |
acetochlor affects the expression of BCL2L1 protein |
CTD |
PMID:25291404 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases expression |
ISO |
acetochlor results in increased expression of BID protein |
CTD |
PMID:25291404 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [acetochlor results in increased expression of CASP3 protein modified form] |
CTD |
PMID:25291404 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [acetochlor results in increased cleavage of CASP9 protein] |
CTD |
PMID:25291404 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases metabolic processing |
ISO |
CYP2B6 protein results in increased metabolism of acetochlor |
CTD |
PMID:11133395 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases metabolic processing |
ISO |
CYP3A4 protein results in increased metabolism of acetochlor |
CTD |
PMID:11133395 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
acetochlor binds to and results in decreased activity of ESR1 protein |
CTD |
PMID:33049310 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
acetochlor binds to and results in decreased activity of ESR2 protein |
CTD |
PMID:33049310 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Gfral |
GDNF family receptor alpha like |
affects response to substance |
ISO |
GFRAL gene SNP affects the susceptibility to acetochlor |
CTD |
PMID:25622337 |
|
NCBI chr 8:76,917,894...76,963,258
Ensembl chr 8:76,918,657...76,959,425
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [acetochlor results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:25291404 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
acetochlor results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [acetochlor results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:25291404 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
affects expression |
ISO |
acetochlor affects the expression of MCL1 protein |
CTD |
PMID:25291404 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Msl1 |
MSL complex subunit 1 |
multiple interactions |
ISO |
[Herbicides results in increased abundance of acetochlor] which affects the methylation of MSL1 gene |
CTD |
PMID:34516295 |
|
NCBI chr10:83,755,380...83,767,147
Ensembl chr10:83,755,720...83,765,726
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
acetochlor binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [acetochlor results in increased cleavage of PARP1 protein] |
CTD |
PMID:25291404 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
acetochlor binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Qsox1 |
quiescin sulfhydryl oxidase 1 |
multiple interactions |
ISO |
[Herbicides results in increased abundance of acetochlor] which affects the methylation of QSOX1 gene |
CTD |
PMID:34516295 |
|
NCBI chr13:67,949,780...67,987,434
Ensembl chr13:67,949,780...67,987,459
|
|
G |
Rimklb |
ribosomal modification protein rimK-like family member B |
affects response to substance |
ISO |
RIMKLB gene SNP affects the susceptibility to acetochlor |
CTD |
PMID:25622337 |
|
NCBI chr 4:155,664,392...155,706,888
Ensembl chr 4:155,664,375...155,706,711
|
|
G |
Rnf126 |
ring finger protein 126 |
multiple interactions |
ISO |
[Herbicides results in increased abundance of acetochlor] which affects the methylation of RNF126 gene |
CTD |
PMID:34516295 |
|
NCBI chr 7:9,939,359...9,946,963
Ensembl chr 7:9,938,229...9,946,738
|
|
G |
Rrp9 |
ribosomal RNA processing 9, U3 small nucleolar RNA binding protein |
multiple interactions |
ISO |
[Herbicides results in increased abundance of acetochlor] which affects the methylation of RRP9 gene |
CTD |
PMID:34516295 |
|
NCBI chr 8:107,116,411...107,126,123
Ensembl chr 8:107,117,471...107,126,123
|
|
G |
Thrb |
thyroid hormone receptor beta |
affects binding multiple interactions |
ISO |
acetochlor binds to THRB protein acetochlor binds to and results in decreased activity of THRB protein |
CTD |
PMID:28973306 PMID:33049310 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Ttc7b |
tetratricopeptide repeat domain 7B |
multiple interactions |
ISO |
[Herbicides results in increased abundance of acetochlor] which affects the methylation of TTC7B gene |
CTD |
PMID:34516295 |
|
NCBI chr 6:119,587,389...119,799,167
Ensembl chr 6:119,587,390...119,799,330
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions increases activity |
ISO |
ABCB1 protein affects the reaction [alachlor results in increased susceptibility to Paclitaxel] alachlor results in increased activity of ABCB1 protein |
CTD |
PMID:18433974 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Ache |
acetylcholinesterase |
increases activity increases expression |
ISO EXP |
alachlor results in increased activity of ACHE protein alachlor results in increased expression of ACHE mRNA |
CTD |
PMID:12419858 PMID:16998629 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acsm4 |
acyl-CoA synthetase medium-chain family member 4 |
affects expression |
EXP |
alachlor affects the expression of ACSM4 mRNA |
CTD |
PMID:19425180 |
|
NCBI chr 1:174,053,931...174,078,345
Ensembl chr 1:174,053,931...174,078,341
|
|
G |
Adarb1 |
adenosine deaminase, RNA-specific, B1 |
increases expression |
EXP |
alachlor results in increased expression of ADARB1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr20:11,222,569...11,350,854
Ensembl chr20:11,222,583...11,350,852
|
|
G |
Adh7 |
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide |
affects expression |
EXP |
alachlor affects the expression of ADH7 mRNA |
CTD |
PMID:19425180 |
|
NCBI chr 2:226,748,724...226,763,183
Ensembl chr 2:226,741,788...226,763,182
|
|
G |
Aen |
apoptosis enhancing nuclease |
affects expression |
EXP |
alachlor affects the expression of AEN mRNA |
CTD |
PMID:19425180 |
|
NCBI chr 1:132,815,094...132,824,522
Ensembl chr 1:132,815,142...132,824,523
|
|
G |
Ago2 |
argonaute RISC catalytic component 2 |
increases expression |
EXP |
alachlor results in increased expression of AGO2 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 7:105,018,202...105,105,118
Ensembl chr 7:105,029,120...105,104,974
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of AKT1 protein; [alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of AKT1 protein |
CTD |
PMID:19883720 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
alachlor inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA] |
CTD |
PMID:29149346 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apod |
apolipoprotein D |
affects expression |
EXP |
alachlor affects the expression of APOD mRNA |
CTD |
PMID:19425180 |
|
NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
alachlor inhibits the reaction [Metribolone results in increased activity of AR protein]; Dihydrotestosterone inhibits the reaction [alachlor results in increased activity of AR protein] |
CTD |
PMID:15064155 PMID:18324785 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arhgap35 |
Rho GTPase activating protein 35 |
affects expression |
EXP |
alachlor affects the expression of ARHGAP35 mRNA |
CTD |
PMID:19425180 |
|
NCBI chr 1:77,202,436...77,319,298
Ensembl chr 1:77,202,436...77,319,298
|
|
G |
Atic |
5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase |
increases expression |
EXP |
alachlor results in increased expression of ATIC mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 9:73,164,846...73,184,897
Ensembl chr 9:73,164,846...73,184,889
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
alachlor results in increased expression of BAX mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions decreases response to substance |
ISO |
alachlor results in increased expression of BCL2 protein fulvestrant inhibits the reaction [alachlor results in increased expression of BCL2 protein]; PK 11195 inhibits the reaction [BCL2 protein results in decreased susceptibility to alachlor] |
CTD |
PMID:10545406 PMID:12730627 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bin1 |
bridging integrator 1 |
increases expression |
EXP |
alachlor results in increased expression of BIN1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr18:24,009,731...24,067,267
Ensembl chr18:24,009,653...24,067,263
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases expression |
EXP |
alachlor results in increased expression of CALCA mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Car2 |
carbonic anhydrase 2 |
increases expression |
EXP |
alachlor results in increased expression of CA2 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Ccnb1 |
cyclin B1 |
increases expression |
EXP |
alachlor results in increased expression of CCNB1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of CCND1 protein |
CTD |
PMID:19883720 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
increases expression |
EXP |
alachlor results in increased expression of CCND2 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Cd200 |
Cd200 molecule |
increases expression |
EXP |
alachlor results in increased expression of CD200 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648
|
|
G |
Cdc123 |
cell division cycle 123 |
increases expression |
EXP |
alachlor results in increased expression of CDC123 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr17:72,459,270...72,503,316
Ensembl chr17:72,459,282...72,503,316
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
increases expression |
EXP |
alachlor results in increased expression of CDK1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Ces5a |
carboxylesterase 5A |
affects expression |
EXP |
alachlor affects the expression of CES5A mRNA |
CTD |
PMID:19425180 |
|
NCBI chr19:11,469,431...11,499,007
Ensembl chr19:11,469,469...11,499,006
|
|
G |
Cgref1 |
cell growth regulator with EF hand domain 1 |
increases expression |
EXP |
alachlor results in increased expression of CGREF1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852
|
|
G |
Clip2 |
CAP-GLY domain containing linker protein 2 |
increases expression |
EXP |
alachlor results in increased expression of CLIP2 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr12:22,163,044...22,227,023
Ensembl chr12:22,163,218...22,227,023
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
increases expression |
EXP |
alachlor results in increased expression of COL11A1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
|
|
G |
Col5a1 |
collagen type V alpha 1 chain |
increases expression |
EXP |
alachlor results in increased expression of COL5A1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
increases expression |
EXP |
alachlor results in increased expression of COL5A2 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 9:47,448,741...47,598,134
Ensembl chr 9:47,448,736...47,598,154
|
|
G |
Cplx2 |
complexin 2 |
increases expression |
EXP |
alachlor results in increased expression of CPLX2 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr17:10,219,577...10,292,835
Ensembl chr17:10,222,347...10,293,855
|
|
G |
Cpz |
carboxypeptidase Z |
increases expression |
EXP |
alachlor results in increased expression of CPZ mRNA |
CTD |
PMID:12419858 |
|
NCBI chr14:75,223,692...75,246,946
Ensembl chr14:75,223,605...75,246,945
|
|
G |
Crabp2 |
cellular retinoic acid binding protein 2 |
increases expression |
EXP |
alachlor results in increased expression of CRABP2 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 2:173,417,004...173,421,352
Ensembl chr 2:173,416,857...173,421,379
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
increases expression |
EXP |
alachlor results in increased expression of CXCR4 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
EXP |
alachlor results in increased expression of CYP1A1 protein |
CTD |
PMID:11850968 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
EXP |
alachlor results in increased expression of CYP1A2 protein |
CTD |
PMID:11850968 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
decreases expression |
EXP |
alachlor results in decreased expression of CYP2A3 protein |
CTD |
PMID:16698726 |
|
NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
alachlor results in increased expression of and results in increased activity of CYP2B1 protein |
CTD |
PMID:11850968 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression |
EXP |
alachlor results in increased expression of CYP2B2 protein |
CTD |
PMID:11850968 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases response to substance |
ISO |
CYP2B6 protein results in decreased susceptibility to alachlor |
CTD |
PMID:16277416 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases metabolic processing increases expression multiple interactions |
ISO |
CYP3A4 protein results in increased metabolism of alachlor alachlor results in increased expression of CYP3A4 mRNA [CYP3A4 protein results in increased metabolism of alachlor] which results in increased abundance of 2-chloro-N-(2,6-diethylphenyl)acetamide |
CTD |
PMID:10475613 PMID:16565514 PMID:18273908 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression |
EXP |
alachlor results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:14613717 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Defa5 |
defensin alpha 5 |
increases expression |
EXP |
alachlor results in increased expression of DEFA5 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr16:70,342,530...70,344,854
Ensembl chr16:70,342,530...70,344,836
|
|
G |
Dmbt1 |
deleted in malignant brain tumors 1 |
increases expression |
EXP |
alachlor results in increased expression of DMBT1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 1:185,617,469...185,696,476
Ensembl chr 1:185,617,294...185,696,478
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
increases expression |
EXP |
alachlor results in increased expression of EIF4EBP1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eln |
elastin |
increases expression |
EXP |
alachlor results in increased expression of ELN mRNA |
CTD |
PMID:12419858 |
|
NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928
|
|
G |
Entpd2 |
ectonucleoside triphosphate diphosphohydrolase 2 |
increases expression |
EXP |
alachlor results in increased expression of ENTPD2 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 3:8,213,575...8,219,094
Ensembl chr 3:8,213,663...8,226,866
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
increases expression |
EXP |
alachlor results in increased expression of ERP29 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376
|
|
G |
Esr1 |
estrogen receptor 1 |
affects binding multiple interactions |
ISO |
alachlor binds to ESR1 protein [Dieldrin co-treated with alachlor] inhibits the reaction [Estradiol binds to ESR1 protein]; alachlor inhibits the reaction [Estradiol binds to ESR1 protein] |
CTD |
PMID:9168004 PMID:14579009 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Fdps |
farnesyl diphosphate synthase |
increases expression |
EXP |
alachlor results in increased expression of FDPS mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fntb |
farnesyltransferase, CAAX box, subunit beta |
increases expression |
EXP |
alachlor results in increased expression of FNTB mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 6:95,536,540...95,619,587
Ensembl chr 6:95,470,683...95,619,586
|
|
G |
Foxa2 |
forkhead box A2 |
increases expression |
EXP |
alachlor results in increased expression of FOXA2 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
increases expression |
EXP |
alachlor results in increased expression of FYN mRNA |
CTD |
PMID:12419858 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
EXP |
alachlor results in increased expression of GADD45A mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
EXP |
alachlor results in increased expression of GCLC protein |
CTD |
PMID:14563481 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
EXP |
alachlor results in increased expression of GCLM protein |
CTD |
PMID:14563481 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gk |
glycerol kinase |
affects expression |
EXP |
alachlor affects the expression of GK mRNA |
CTD |
PMID:19425180 |
|
NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631
|
|
G |
Gng8 |
G protein subunit gamma 8 |
increases expression |
EXP |
alachlor results in increased expression of GNG8 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 1:77,564,512...77,568,371
Ensembl chr 1:77,564,515...77,568,371
|
|
G |
Gpx6 |
glutathione peroxidase 6 |
increases expression |
EXP |
alachlor results in increased expression of GPX6 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr17:43,408,472...43,416,091
Ensembl chr17:43,408,472...43,416,091
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of GSK3B protein |
CTD |
PMID:19883720 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hbb |
hemoglobin subunit beta |
affects binding |
EXP |
alachlor binds to HBB protein |
CTD |
PMID:10075819 |
|
NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
|
|
G |
Hdc |
histidine decarboxylase |
increases expression |
EXP |
alachlor results in increased expression of HDC mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 3:113,847,256...113,865,334
Ensembl chr 3:113,847,260...113,865,341
|
|
G |
Hmgb2 |
high mobility group box 2 |
increases expression |
EXP |
alachlor results in increased expression of HMGB2 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140 Ensembl chr 1:32,710,658...32,713,140
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
EXP |
alachlor results in increased expression of HMOX1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnpa1 |
heterogeneous nuclear ribonucleoprotein A1 |
increases expression |
EXP |
alachlor results in increased expression of HNRNPA1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 7:134,375,318...134,381,610
Ensembl chr 7:134,375,150...134,381,609
|
|
G |
Homer2 |
homer scaffold protein 2 |
increases expression |
EXP |
alachlor results in increased expression of HOMER2 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 1:135,558,977...135,659,780
Ensembl chr 1:135,567,414...135,659,772
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
increases expression |
EXP |
alachlor results in increased expression of HSP90AA1 mRNA alternative form |
CTD |
PMID:8792849 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
alachlor inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; alachlor inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 protein] |
CTD |
PMID:15907790 PMID:18177342 |
|
NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
IgG-2a |
gamma-2a immunoglobulin heavy chain |
affects expression |
EXP |
alachlor affects the expression of IGG-2A mRNA |
CTD |
PMID:19425180 |
|
|
|
G |
Jchain |
joining chain of multimeric IgA and IgM |
affects expression |
EXP |
alachlor affects the expression of JCHAIN mRNA |
CTD |
PMID:19425180 |
|
NCBI chr14:19,538,927...19,547,023
Ensembl chr14:19,538,952...19,546,298
|
|
G |
Kif3b |
kinesin family member 3B |
affects expression |
EXP |
alachlor affects the expression of KIF3B mRNA |
CTD |
PMID:19425180 |
|
NCBI chr 3:141,758,466...141,798,012
Ensembl chr 3:141,758,466...141,797,963
|
|
G |
Klf6 |
KLF transcription factor 6 |
increases expression |
EXP |
alachlor results in increased expression of KLF6 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Lgals1 |
galectin 1 |
increases expression |
EXP |
alachlor results in increased expression of LGALS1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345
|
|
G |
Lgi4 |
leucine-rich repeat LGI family, member 4 |
affects expression |
EXP |
alachlor affects the expression of LGI4 mRNA |
CTD |
PMID:19425180 |
|
NCBI chr 1:86,294,539...86,305,909
Ensembl chr 1:86,295,074...86,304,874
|
|
G |
Lxn |
latexin |
increases expression |
EXP |
alachlor results in increased expression of LXN mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 2:151,727,556...151,733,426
Ensembl chr 2:151,727,102...151,733,460
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
increases expression |
EXP |
alachlor results in increased expression of MAP3K1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463
|
|
G |
Marcks |
myristoylated alanine rich protein kinase C substrate |
increases expression |
EXP |
alachlor results in increased expression of MARCKS mRNA |
CTD |
PMID:12419858 |
|
NCBI chr20:40,685,315...40,691,012
Ensembl chr20:40,685,315...40,691,012
|
|
G |
Mcm6 |
minichromosome maintenance complex component 6 |
increases expression |
EXP |
alachlor results in increased expression of MCM6 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960
|
|
G |
Mgat2 |
alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase |
increases expression |
EXP |
alachlor results in increased expression of MGAT2 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 6:87,656,360...87,658,849
Ensembl chr 6:87,656,349...87,658,177
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression increases activity |
EXP |
alachlor results in increased expression of MMP2 mRNA alachlor results in increased activity of MMP2 protein |
CTD |
PMID:12419858 PMID:16178123 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
EXP |
alachlor results in increased expression of MMP9 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Moxd2 |
monooxygenase, DBH-like 2 |
affects expression |
EXP |
alachlor affects the expression of MOXD2 mRNA |
CTD |
PMID:19425180 |
|
NCBI chr 4:69,724,693...69,733,188
Ensembl chr 4:69,724,239...69,733,299
|
|
G |
Mt3 |
metallothionein 3 |
increases expression |
EXP |
alachlor results in increased expression of MT3 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr19:10,848,754...10,850,158
Ensembl chr19:10,848,755...10,850,158
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
increases expression |
EXP |
alachlor results in increased expression of MVD mRNA |
CTD |
PMID:12419858 |
|
NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of MYC protein |
CTD |
PMID:19883720 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases activity |
ISO |
alachlor results in increased activity of NFE2L2 protein |
CTD |
PMID:20143881 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
alachlor inhibits the reaction [Lipopolysaccharides affects the localization of NFKB1 protein]; alachlor inhibits the reaction [Lipopolysaccharides results in increased activity of NFKB1 protein] |
CTD |
PMID:15907790 PMID:17015962 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
alachlor inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein] |
CTD |
PMID:15907790 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions |
ISO |
alachlor inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIB protein] |
CTD |
PMID:15907790 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
alachlor inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; alachlor inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:15907790 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO EXP |
alachlor results in increased activity of NR1I2 protein alachlor binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:14613717 PMID:16565514 PMID:21115097 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO |
alachlor results in increased activity of NR1I3 protein |
CTD |
PMID:28927721 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
multiple interactions |
ISO |
alachlor inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; alachlor inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein] |
CTD |
PMID:29149346 |
|
NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885
|
|
G |
Obp2b |
odorant binding protein 2B |
increases expression |
EXP |
alachlor results in increased expression of OBP2B mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 3:8,582,074...8,585,258
Ensembl chr 3:8,582,074...8,585,258
|
|
G |
Or7g31 |
olfactory receptor family 7 subfamily G member 31 |
affects expression |
EXP |
alachlor affects the expression of OR7G2 mRNA |
CTD |
PMID:19425180 |
|
NCBI chr 8:17,056,179...17,057,117
Ensembl chr 8:17,053,661...17,057,239
|
|
G |
Pcolce |
procollagen C-endopeptidase enhancer |
increases expression |
EXP |
alachlor results in increased expression of PCOLCE mRNA |
CTD |
PMID:12419858 |
|
NCBI chr12:19,084,191...19,090,508
Ensembl chr12:19,084,210...19,090,508
|
|
G |
Pcsk6 |
proprotein convertase subtilisin/kexin type 6 |
increases expression |
EXP |
alachlor results in increased expression of PCSK6 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 1:119,428,978...119,627,626
Ensembl chr 1:119,429,265...119,627,596
|
|
G |
Pdk2 |
pyruvate dehydrogenase kinase 2 |
increases expression |
EXP |
alachlor results in increased expression of PDK2 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr10:79,972,550...79,987,074
Ensembl chr10:79,972,556...79,987,085
|
|
G |
Pgr |
progesterone receptor |
multiple interactions affects binding |
ISO |
alachlor inhibits the reaction [Progesterone binds to PGR protein] alachlor binds to PGR protein |
CTD |
PMID:14579009 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Phex |
phosphate regulating endopeptidase X-linked |
increases expression |
EXP |
alachlor results in increased expression of PHEX mRNA |
CTD |
PMID:12419858 |
|
NCBI chr X:37,607,553...37,856,183
Ensembl chr X:37,610,760...37,854,469
|
|
G |
Plp1 |
proteolipid protein 1 |
affects expression |
EXP |
alachlor affects the expression of PLP1 mRNA |
CTD |
PMID:19425180 |
|
NCBI chr X:100,184,039...100,201,035
Ensembl chr X:100,185,767...100,201,032
|
|
G |
Polr3g |
RNA polymerase III subunit G |
affects expression |
EXP |
alachlor affects the expression of POLR3G mRNA |
CTD |
PMID:19425180 |
|
NCBI chr 2:11,945,215...11,986,125
Ensembl chr 2:11,945,217...11,986,125
|
|
G |
Prph |
peripherin |
increases expression |
EXP |
alachlor results in increased expression of PRPH mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 7:130,218,149...130,222,136
Ensembl chr 7:130,218,357...130,222,136
|
|
G |
Ptgds |
prostaglandin D2 synthase |
affects expression |
EXP |
alachlor affects the expression of PTGDS mRNA |
CTD |
PMID:19425180 |
|
NCBI chr 3:8,281,899...8,284,833
Ensembl chr 3:8,281,899...8,284,833
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
increases expression |
EXP |
alachlor results in increased expression of PTGR1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of PTK2B protein modified form |
CTD |
PMID:19883720 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Qdpr |
quinoid dihydropteridine reductase |
increases expression |
EXP |
alachlor results in increased expression of QDPR mRNA |
CTD |
PMID:12419858 |
|
NCBI chr14:65,670,251...65,683,853
Ensembl chr14:65,670,131...65,683,854
|
|
G |
Qprt |
quinolinate phosphoribosyltransferase |
affects expression |
EXP |
alachlor affects the expression of QPRT mRNA |
CTD |
PMID:19425180 |
|
NCBI chr 1:181,718,189...181,733,486
Ensembl chr 1:181,718,190...181,733,486
|
|
G |
Rassf8 |
Ras association domain family member 8 |
affects expression |
EXP |
alachlor affects the expression of RASSF8 mRNA |
CTD |
PMID:19425180 |
|
NCBI chr 4:178,716,110...178,798,042
Ensembl chr 4:178,719,992...178,796,690
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
alachlor inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein] |
CTD |
PMID:15907790 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rnf138 |
ring finger protein 138 |
affects expression |
EXP |
alachlor affects the expression of RNF138 mRNA |
CTD |
PMID:19425180 |
|
NCBI chr18:12,291,557...12,315,931
Ensembl chr18:12,291,590...12,315,930
|
|
G |
RT1-DMa |
RT1 class II, locus DMa |
increases expression |
EXP |
alachlor results in increased expression of HLA-DMA mRNA |
CTD |
PMID:12419858 |
|
NCBI chr20:4,707,028...4,710,432
Ensembl chr20:4,707,028...4,710,432
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
increases expression |
EXP |
alachlor results in increased expression of S100A8 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
EXP |
alachlor results in increased expression of S100A9 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Scrg1 |
stimulator of chondrogenesis 1 |
affects expression |
EXP |
alachlor affects the expression of SCRG1 mRNA |
CTD |
PMID:19425180 |
|
NCBI chr16:32,760,028...32,788,299
Ensembl chr16:32,760,028...32,788,299
|
|
G |
Sec24c |
SEC24 homolog C, COPII coat complex component |
affects expression |
EXP |
alachlor affects the expression of SEC24C mRNA |
CTD |
PMID:19425180 |
|
NCBI chr15:3,602,460...3,624,524
Ensembl chr15:3,602,460...3,624,422
|
|
G |
Serpinb11 |
serpin family B member 11 |
affects expression |
EXP |
alachlor affects the expression of SERPINB11 mRNA |
CTD |
PMID:19425180 |
|
NCBI chr13:23,304,775...23,344,604
Ensembl chr13:23,304,456...23,344,604
|
|
G |
Serpinh1 |
serpin family H member 1 |
increases expression |
EXP |
alachlor results in increased expression of SERPINH1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
increases expression |
EXP |
alachlor results in increased expression of SLC16A1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc22a20 |
solute carrier family 22 member 20 |
affects expression |
EXP |
alachlor affects the expression of SLC22A20 mRNA |
CTD |
PMID:19425180 |
|
NCBI chr 1:203,257,374...203,273,854
Ensembl chr 1:203,257,374...203,273,822
|
|
G |
Slc25a35 |
solute carrier family 25, member 35 |
affects expression |
EXP |
alachlor affects the expression of SLC25A35 mRNA |
CTD |
PMID:19425180 |
|
NCBI chr10:53,672,851...53,677,501
Ensembl chr10:53,673,340...53,698,160
|
|
G |
Slc4a2 |
solute carrier family 4 member 2 |
increases expression |
EXP |
alachlor results in increased expression of SLC4A2 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965
|
|
G |
Slc6a13 |
solute carrier family 6 member 13 |
affects expression |
EXP |
alachlor affects the expression of SLC6A13 mRNA |
CTD |
PMID:19425180 |
|
NCBI chr 4:154,539,246...154,577,784
Ensembl chr 4:154,540,468...154,576,152
|
|
G |
Slc7a1 |
solute carrier family 7 member 1 |
increases expression |
EXP |
alachlor results in increased expression of SLC7A1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr12:6,628,288...6,703,849
Ensembl chr12:6,628,007...6,703,849
|
|
G |
Snrpn |
small nuclear ribonucleoprotein polypeptide N |
affects expression |
EXP |
alachlor affects the expression of SNRPN mRNA |
CTD |
PMID:19425180 |
|
NCBI chr 1:111,101,327...111,123,400
Ensembl chr 1:111,101,329...111,123,634
|
|
G |
Snurf |
SNRPN upstream open reading frame |
affects expression |
EXP |
alachlor affects the expression of SNURF mRNA |
CTD |
PMID:19425180 |
|
NCBI chr 1:111,101,327...111,123,634
Ensembl chr 1:111,101,329...111,123,634
|
|
G |
Sox11 |
SRY-box transcription factor 11 |
increases expression |
EXP |
alachlor results in increased expression of SOX11 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 6:44,008,333...44,010,354
Ensembl chr 6:44,008,340...44,010,354
|
|
G |
Srpx |
sushi-repeat-containing protein, X-linked |
increases expression |
EXP |
alachlor results in increased expression of SRPX mRNA |
CTD |
PMID:12419858 |
|
NCBI chr X:12,676,984...12,751,296
Ensembl chr X:12,566,645...12,747,882
|
|
G |
Tfrc |
transferrin receptor |
increases expression |
EXP |
alachlor results in increased expression of TFRC mRNA |
CTD |
PMID:12419858 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
EXP |
alachlor results in increased expression of TIMP1 mRNA |
CTD |
PMID:12419858 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnc |
tenascin C |
increases expression |
EXP |
alachlor results in increased expression of TNC mRNA |
CTD |
PMID:12419858 |
|
NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
alachlor promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:15256756 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Top2a |
DNA topoisomerase II alpha |
increases expression |
EXP |
alachlor results in increased expression of TOP2A mRNA |
CTD |
PMID:12419858 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
increases expression |
EXP |
alachlor results in increased expression of TSHB protein |
CTD |
PMID:8812207 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Dihydrotestosterone inhibits the reaction [anilofos results in increased activity of AR protein] |
CTD |
PMID:15064155 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
anilofos binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:21115097 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
|
G |
Alb |
albumin |
increases expression |
ISO |
butachlor results in increased expression of ALB protein |
CTD |
PMID:34351278 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression |
ISO |
butachlor results in decreased expression of APAF1 mRNA |
CTD |
PMID:34351278 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Ar |
androgen receptor |
increases activity |
ISO |
butachlor results in increased activity of AR protein |
CTD |
PMID:20143881 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Atg5 |
autophagy related 5 |
decreases expression increases expression |
ISO |
butachlor results in decreased expression of ATG5 mRNA butachlor results in increased expression of ATG5 protein |
CTD |
PMID:34351278 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Casp3 |
caspase 3 |
decreases expression |
ISO |
butachlor results in decreased expression of CASP3 mRNA |
CTD |
PMID:34351278 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
ISO |
butachlor results in decreased expression of CASP9 mRNA |
CTD |
PMID:34351278 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cycs |
cytochrome c, somatic |
decreases expression |
ISO |
butachlor results in decreased expression of CYCS mRNA |
CTD |
PMID:34351278 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases metabolic processing |
ISO |
CYP2B6 protein results in increased metabolism of butachlor |
CTD |
PMID:11133395 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases metabolic processing |
ISO |
CYP3A4 protein results in increased metabolism of butachlor |
CTD |
PMID:11133395 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases activity |
ISO |
butachlor results in decreased activity of DIO1 protein |
CTD |
PMID:29228274 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
ISO |
butachlor results in decreased expression of IL10 mRNA |
CTD |
PMID:34351278 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression |
ISO |
butachlor results in increased expression of MAP1LC3B protein |
CTD |
PMID:34351278 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases expression |
ISO |
butachlor results in decreased expression of MTOR mRNA |
CTD |
PMID:34351278 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
increases activity |
ISO |
butachlor results in increased activity of NR1H4 protein |
CTD |
PMID:20143881 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
increases activity |
ISO |
butachlor results in increased activity of NR3C1 protein |
CTD |
PMID:20143881 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression |
ISO |
butachlor results in decreased expression of SQSTM1 mRNA; butachlor results in decreased expression of SQSTM1 protein |
CTD |
PMID:34351278 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Thrb |
thyroid hormone receptor beta |
affects binding |
ISO |
butachlor binds to THRB protein |
CTD |
PMID:28973306 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression |
ISO |
butachlor results in decreased expression of TNF mRNA |
CTD |
PMID:34351278 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Anxa2 |
annexin A2 |
decreases expression |
ISO |
Carboxin results in decreased expression of ANXA2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
decreases expression |
ISO |
Carboxin results in decreased expression of BBC3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport multiple interactions increases response to substance |
ISO EXP |
ABCB1 protein results in increased transport of Fentanyl tariquidar inhibits the reaction [ABCB1 protein results in increased transport of Fentanyl] ABCB1 protein results in increased susceptibility to Fentanyl |
CTD |
PMID:29669042 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Acan |
aggrecan |
decreases expression |
EXP |
Fentanyl results in decreased expression of ACAN mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Adamts14 |
ADAM metallopeptidase with thrombospondin type 1 motif, 14 |
decreases expression |
EXP |
Fentanyl results in decreased expression of ADAMTS14 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr20:29,143,029...29,219,846
Ensembl chr20:29,144,354...29,219,866
|
|
G |
Adamtsl3 |
ADAMTS-like 3 |
affects expression |
EXP |
Fentanyl affects the expression of ADAMTSL3 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 1:136,288,793...136,596,986
Ensembl chr 1:136,288,793...136,596,986
|
|
G |
Akap5 |
A-kinase anchoring protein 5 |
increases expression |
EXP |
Fentanyl results in increased expression of AKAP5 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 6:95,051,527...95,061,075
Ensembl chr 6:95,051,537...95,061,578
|
|
G |
Apln |
apelin |
decreases expression |
EXP |
Fentanyl results in decreased expression of APLN mRNA |
CTD |
PMID:36032789 |
|
NCBI chr X:127,180,801...127,213,567
Ensembl chr X:127,203,823...127,213,391
|
|
G |
Arrb2 |
arrestin, beta 2 |
affects localization multiple interactions |
ISO EXP |
Fentanyl affects the localization of ARRB2 protein [Fentanyl binds to and results in increased activity of OPRM1 protein] which results in increased activity of ARRB2 protein |
CTD |
PMID:27030709 PMID:35477798 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
affects expression |
EXP |
Fentanyl affects the expression of BDNF mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bgn |
biglycan |
affects expression |
EXP |
Fentanyl affects the expression of BGN mRNA |
CTD |
PMID:36032789 |
|
NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
increases expression |
EXP |
Fentanyl results in increased expression of BIRC3 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Bst2 |
bone marrow stromal cell antigen 2 |
increases expression |
EXP |
Fentanyl results in increased expression of BST2 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr16:18,216,605...18,220,979
Ensembl chr16:18,217,407...18,220,979
|
|
G |
C3 |
complement C3 |
increases expression |
EXP |
Fentanyl results in increased expression of C3 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Cacna1e |
calcium voltage-gated channel subunit alpha1 E |
affects expression |
EXP |
Fentanyl affects the expression of CACNA1E mRNA |
CTD |
PMID:36032789 |
|
NCBI chr13:66,574,659...67,063,443
Ensembl chr13:66,581,920...66,894,450
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions |
EXP |
Fentanyl inhibits the reaction [Potassium Chloride results in increased secretion of CALCA protein]; Naloxone inhibits the reaction [Fentanyl inhibits the reaction [Potassium Chloride results in increased secretion of CALCA protein]] |
CTD |
PMID:27030709 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Cckbr |
cholecystokinin B receptor |
decreases expression |
EXP |
Fentanyl results in decreased expression of CCKBR mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
EXP |
Fentanyl results in increased expression of CCL2 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression |
EXP |
Fentanyl results in increased expression of CCL20 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression |
EXP |
Fentanyl results in increased expression of CCL7 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Cfb |
complement factor B |
increases expression |
EXP |
Fentanyl results in increased expression of CFB mRNA |
CTD |
PMID:36032789 |
|
NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
increases expression |
EXP |
Fentanyl results in increased expression of CHI3L1 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787
|
|
G |
Clstn2 |
calsyntenin 2 |
affects expression |
EXP |
Fentanyl affects the expression of CLSTN2 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 8:98,020,406...98,637,232
Ensembl chr 8:98,021,666...98,637,731
|
|
G |
Cntf |
ciliary neurotrophic factor |
increases expression |
EXP |
Fentanyl results in increased expression of CNTF mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 1:209,887,854...209,889,877
Ensembl chr 1:209,887,854...209,889,877
|
|
G |
Col15a1 |
collagen type XV alpha 1 chain |
increases expression |
EXP |
Fentanyl results in increased expression of COL15A1 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 5:61,501,963...61,607,591
Ensembl chr 5:61,501,963...61,607,591
|
|
G |
Col26a1 |
collagen type XXVI alpha 1 chain |
increases expression |
EXP |
Fentanyl results in increased expression of COL26A1 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr12:19,792,693...19,938,556
Ensembl chr12:19,792,728...19,938,556
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
affects expression |
EXP |
Fentanyl affects the expression of COL3A1 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Crh |
corticotropin releasing hormone |
affects expression increases expression |
EXP |
Fentanyl affects the expression of CRH mRNA Fentanyl results in increased expression of CRH mRNA |
CTD |
PMID:18819432 PMID:36032789 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crlf1 |
cytokine receptor-like factor 1 |
affects expression |
EXP |
Fentanyl affects the expression of CRLF1 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr16:18,924,722...18,936,049
Ensembl chr16:18,924,722...18,935,997
|
|
G |
Csf1 |
colony stimulating factor 1 |
increases expression |
EXP |
Fentanyl results in increased expression of CSF1 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
EXP |
Fentanyl results in increased expression of CXCL1 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
EXP |
Fentanyl results in increased expression of CXCL10 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
increases expression |
EXP |
Fentanyl results in increased expression of CXCL11 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression |
EXP |
Fentanyl results in increased expression of CXCL12 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl13 |
C-X-C motif chemokine ligand 13 |
increases expression |
EXP |
Fentanyl results in increased expression of CXCL13 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933
|
|
G |
Cxcl16 |
C-X-C motif chemokine ligand 16 |
increases expression |
EXP |
Fentanyl results in increased expression of CXCL16 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases activity |
ISO |
Fentanyl results in increased activity of CYP2B6 protein |
CTD |
PMID:35914676 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases metabolic processing |
ISO |
CYP3A4 protein results in increased metabolism of Fentanyl |
CTD |
PMID:11811955 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dcn |
decorin |
increases expression |
EXP |
Fentanyl results in increased expression of DCN mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Ednrb |
endothelin receptor type B |
decreases expression |
EXP |
Fentanyl results in decreased expression of EDNRB mRNA |
CTD |
PMID:36032789 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Fbln5 |
fibulin 5 |
decreases expression |
EXP |
Fentanyl results in decreased expression of FBLN5 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 6:120,899,219...120,977,829
Ensembl chr 6:120,899,224...120,977,755
|
|
G |
Fgr |
FGR proto-oncogene, Src family tyrosine kinase |
increases expression |
EXP |
Fentanyl results in increased expression of FGR mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 5:145,189,814...145,219,571
Ensembl chr 5:145,189,841...145,217,326
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Fentanyl results in increased expression of FOS protein |
CTD |
PMID:7970238 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gast |
gastrin |
multiple interactions |
EXP |
[fluanisone co-treated with Fentanyl co-treated with Midazolam] inhibits the reaction [GAST protein results in increased secretion of Histamine] |
CTD |
PMID:10864877 |
|
NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496
|
|
G |
Gbp2 |
guanylate binding protein 2 |
increases expression |
EXP |
Fentanyl results in increased expression of GBP2 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571
|
|
G |
Grem1 |
gremlin 1, DAN family BMP antagonist |
decreases expression |
EXP |
Fentanyl results in decreased expression of GREM1 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:100,512,313...100,524,082
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
affects expression |
EXP |
Fentanyl affects the expression of GRIN2A mRNA |
CTD |
PMID:36032789 |
|
NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
affects expression |
EXP |
Fentanyl affects the expression of GRIN2B mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Grm1 |
glutamate metabotropic receptor 1 |
affects expression |
EXP |
Fentanyl affects the expression of GRM1 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 1:5,058,285...5,453,170
Ensembl chr 1:5,058,292...5,453,170
|
|
G |
Grm3 |
glutamate metabotropic receptor 3 |
affects expression |
EXP |
Fentanyl affects the expression of GRM3 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 4:24,364,854...24,643,972
Ensembl chr 4:24,365,115...24,609,804
|
|
G |
Has1 |
hyaluronan synthase 1 |
decreases expression |
EXP |
Fentanyl results in decreased expression of HAS1 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 1:58,693,411...58,705,653
Ensembl chr 1:58,693,411...58,705,397
|
|
G |
Hcrtr1 |
hypocretin receptor 1 |
decreases expression |
EXP |
Fentanyl results in decreased expression of HCRTR1 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 5:142,477,214...142,486,674
Ensembl chr 5:142,477,214...142,486,674
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
affects expression |
EXP |
Fentanyl affects the expression of HTR2A mRNA |
CTD |
PMID:36032789 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
increases expression |
EXP |
Fentanyl results in increased expression of IFIT3 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
EXP |
Fentanyl results in increased expression of IL1A mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il2 |
interleukin 2 |
decreases expression |
ISO |
Fentanyl results in decreased expression of IL2 mRNA |
CTD |
PMID:23965172 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il4 |
interleukin 4 |
increases expression |
ISO |
Fentanyl results in increased expression of IL4 mRNA |
CTD |
PMID:23965172 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il7 |
interleukin 7 |
increases expression |
EXP |
Fentanyl results in increased expression of IL7 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 2:94,235,219...94,280,075
Ensembl chr 2:94,234,766...94,280,075
|
|
G |
Irf7 |
interferon regulatory factor 7 |
increases expression |
EXP |
Fentanyl results in increased expression of IRF7 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
increases expression |
EXP |
Fentanyl results in increased expression of ISG15 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435
|
|
G |
Itga11 |
integrin subunit alpha 11 |
increases expression |
EXP |
Fentanyl results in increased expression of ITGA11 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 8:63,145,998...63,254,714
Ensembl chr 8:63,146,001...63,254,407
|
|
G |
Itgal |
integrin subunit alpha L |
increases expression |
EXP |
Fentanyl results in increased expression of ITGAL mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Fentanyl results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Lamb3 |
laminin subunit beta 3 |
decreases expression |
EXP |
Fentanyl results in decreased expression of LAMB3 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
affects expression |
EXP |
Fentanyl affects the expression of LAMC2 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
EXP |
Fentanyl results in increased expression of LCN2 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Lox |
lysyl oxidase |
decreases expression |
EXP |
Fentanyl results in decreased expression of LOX mRNA |
CTD |
PMID:36032789 |
|
NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477
|
|
G |
Loxl1 |
lysyl oxidase-like 1 |
increases expression |
EXP |
Fentanyl results in increased expression of LOXL1 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 8:58,691,763...58,716,365
Ensembl chr 8:58,692,593...58,716,356
|
|
G |
Loxl2 |
lysyl oxidase-like 2 |
decreases expression |
EXP |
Fentanyl results in decreased expression of LOXL2 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr15:44,683,449...44,773,067
Ensembl chr15:44,683,880...44,773,067
|
|
G |
Ltb |
lymphotoxin beta |
increases expression |
EXP |
Fentanyl results in increased expression of LTB mRNA |
CTD |
PMID:36032789 |
|
NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
Fentanyl results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:23965172 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
Fentanyl results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:23965172 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mas1 |
MAS1 proto-oncogene, G protein-coupled receptor |
decreases expression |
EXP |
Fentanyl results in decreased expression of MAS1 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression |
EXP |
Fentanyl results in increased expression of MMP2 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression |
EXP |
Fentanyl results in decreased expression of MMP9 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mx1 |
MX dynamin like GTPase 1 |
increases expression |
EXP |
Fentanyl results in increased expression of MX1 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr11:36,799,659...36,825,209
Ensembl chr11:36,799,660...36,823,507
|
|
G |
Mx2 |
MX dynamin like GTPase 2 |
increases expression |
EXP |
Fentanyl results in increased expression of MX2 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr11:36,905,698...36,936,308
Ensembl chr11:36,906,111...36,930,342
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases expression |
ISO EXP |
Fentanyl results in increased expression of NFKBIA protein Fentanyl results in increased expression of NFKBIA mRNA |
CTD |
PMID:22258905 PMID:36032789 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nid2 |
nidogen 2 |
decreases expression |
EXP |
Fentanyl results in decreased expression of NID2 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr15:4,458,082...4,513,808
Ensembl chr15:4,458,084...4,513,843
|
|
G |
Nppc |
natriuretic peptide C |
affects expression |
EXP |
Fentanyl affects the expression of NPPC mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 9:87,320,051...87,324,251
Ensembl chr 9:87,320,051...87,324,251
|
|
G |
Nts |
neurotensin |
decreases expression |
EXP |
Fentanyl results in decreased expression of NTS mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
G |
Oasl |
2'-5'-oligoadenylate synthetase-like |
increases expression |
EXP |
Fentanyl results in increased expression of OASL mRNA |
CTD |
PMID:36032789 |
|
NCBI chr12:41,682,900...41,695,641
Ensembl chr12:41,682,900...41,695,641
|
|
G |
Oprd1 |
opioid receptor, delta 1 |
affects binding |
EXP |
Fentanyl binds to OPRD1 protein |
CTD |
PMID:35477798 |
|
NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960
|
|
G |
Oprk1 |
opioid receptor, kappa 1 |
affects binding |
EXP |
Fentanyl binds to OPRK1 protein |
CTD |
PMID:35477798 |
|
NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
increases phosphorylation multiple interactions |
ISO EXP |
Fentanyl results in increased phosphorylation of OPRM1 protein [Fentanyl binds to and results in increased activity of OPRM1 protein] which results in increased activity of ARRB2 protein; Fentanyl binds to and results in increased activity of OPRM1 protein |
CTD |
PMID:17240843 PMID:21957251 PMID:23300227 PMID:35477798 |
|
NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409
|
|
G |
P4ha2 |
prolyl 4-hydroxylase subunit alpha 2 |
decreases expression |
EXP |
Fentanyl results in decreased expression of P4HA2 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr10:38,243,136...38,271,983
Ensembl chr10:38,243,139...38,287,314
|
|
G |
Pdyn |
prodynorphin |
increases expression |
EXP |
Fentanyl results in increased expression of PDYN protein |
CTD |
PMID:19200067 |
|
NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334
|
|
G |
Pf4 |
platelet factor 4 |
increases expression |
EXP |
Fentanyl results in increased expression of PF4 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365
|
|
G |
Pld2 |
phospholipase D2 |
increases activity |
ISO |
Fentanyl results in increased activity of PLD2 protein |
CTD |
PMID:23965172 |
|
NCBI chr10:55,256,326...55,274,192
Ensembl chr10:55,256,359...55,272,808
|
|
G |
Pomc |
proopiomelanocortin |
decreases expression multiple interactions |
ISO |
Fentanyl results in decreased expression of POMC protein alternative form [Fentanyl co-treated with Morphine] results in decreased expression of POMC protein alternative form |
CTD |
PMID:20084599 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Prlhr |
prolactin releasing hormone receptor |
decreases expression |
EXP |
Fentanyl results in decreased expression of PRLHR mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 1:259,606,704...259,608,391
Ensembl chr 1:259,606,704...259,608,391
|
|
G |
Psmb9 |
proteasome 20S subunit beta 9 |
increases expression |
EXP |
Fentanyl results in increased expression of PSMB9 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr20:4,667,044...4,672,512
Ensembl chr20:4,666,046...4,672,512
|
|
G |
Pthlh |
parathyroid hormone-like hormone |
affects expression |
EXP |
Fentanyl affects the expression of PTHLH mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847
|
|
G |
Ptx3 |
pentraxin 3 |
increases expression |
EXP |
Fentanyl results in increased expression of PTX3 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
|
|
G |
Reln |
reelin |
increases expression |
EXP |
Fentanyl results in increased expression of RELN mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 4:12,736,177...13,162,956
Ensembl chr 4:12,736,130...13,162,211
|
|
G |
Ren |
renin |
multiple interactions |
ISO |
[Fentanyl co-treated with Isoflurane] results in decreased expression of REN protein |
CTD |
PMID:3284271 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
increases expression |
EXP |
Fentanyl results in increased expression of S100A8 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
Scg2 |
secretogranin II |
affects expression |
EXP |
Fentanyl affects the expression of SCG2 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 9:80,803,074...80,808,646
Ensembl chr 9:80,803,075...80,821,097
|
|
G |
Sema3a |
semaphorin 3A |
decreases expression |
EXP |
Fentanyl results in decreased expression of SEMA3A mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 4:21,282,398...21,754,834
Ensembl chr 4:21,287,982...21,494,432
|
|
G |
Slc11a1 |
solute carrier family 11 member 1 |
increases expression |
EXP |
Fentanyl results in increased expression of SLC11A1 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 9:75,957,193...75,968,115
Ensembl chr 9:75,957,316...75,968,101
|
|
G |
Slc8a2 |
solute carrier family 8 member A2 |
affects expression |
EXP |
Fentanyl affects the expression of SLC8A2 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 1:76,816,583...76,852,928
Ensembl chr 1:76,808,725...76,847,072
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
EXP |
Fentanyl results in increased expression of SOD2 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sorcs3 |
sortilin-related VPS10 domain containing receptor 3 |
decreases expression |
EXP |
Fentanyl results in decreased expression of SORCS3 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 1:247,099,178...247,734,027
Ensembl chr 1:247,099,408...247,734,027
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
affects expression |
EXP |
Fentanyl affects the expression of SPP1 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Tlr2 |
toll-like receptor 2 |
increases expression |
EXP |
Fentanyl results in increased expression of TLR2 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tnfrsf9 |
TNF receptor superfamily member 9 |
increases expression |
EXP |
Fentanyl results in increased expression of TNFRSF9 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression |
EXP |
Fentanyl results in increased expression of VCAM1 mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
EXP |
Fentanyl results in decreased expression of VEGFA mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vgf |
VGF nerve growth factor inducible |
affects expression |
EXP |
Fentanyl affects the expression of VGF mRNA |
CTD |
PMID:36032789 |
|
NCBI chr12:19,637,313...19,645,123
Ensembl chr12:19,637,320...19,640,341
|
|
G |
Wnt10a |
Wnt family member 10A |
affects expression |
EXP |
Fentanyl affects the expression of WNT10A mRNA |
CTD |
PMID:36032789 |
|
NCBI chr 9:76,349,931...76,362,400
Ensembl chr 9:76,349,931...76,362,400
|
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
multiple interactions |
ISO |
hydroxyflutamide inhibits the reaction [Dihydrotestosterone results in increased expression of ADAMTS1 mRNA]; hydroxyflutamide inhibits the reaction [Dihydrotestosterone results in increased expression of ADAMTS1 protein] |
CTD |
PMID:17018655 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
EXP |
hydroxyflutamide results in increased phosphorylation of AKT1 protein hydroxyflutamide promotes the reaction [Testosterone results in increased phosphorylation of AKT1 protein]; wortmannin inhibits the reaction [hydroxyflutamide results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:26437446 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Ar |
androgen receptor |
decreases activity decreases phosphorylation increases response to substance multiple interactions affects activity affects binding |
ISO EXP |
hydroxyflutamide results in decreased activity of AR protein hydroxyflutamide results in decreased phosphorylation of AR protein AR protein mutant form results in increased susceptibility to hydroxyflutamide [AR protein mutant form results in increased susceptibility to hydroxyflutamide] which results in increased activity of AR protein mutant form; hydroxyflutamide binds to and results in decreased activity of AR protein; hydroxyflutamide binds to and results in increased activity of AR protein; hydroxyflutamide binds to and results in increased activity of AR protein mutant form; hydroxyflutamide inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; hydroxyflutamide inhibits the reaction [[Dihydrotestosterone co-treated with Estradiol] results in decreased expression of AR mRNA]; hydroxyflutamide inhibits the reaction [[Dihydrotestosterone co-treated with Estradiol] results in decreased expression of AR protein]; hydroxyflutamide inhibits the reaction [Cadmium Chloride binds to AR protein]; hydroxyflutamide inhibits the reaction [Cadmium Chloride results in decreased expression of AR mRNA]; hydroxyflutamide inhibits the reaction [Cadmium Chloride results in decreased expression of AR protein]; hydroxyflutamide inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; hydroxyflutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [Estradiol results in decreased expression of AR protein]]; hydroxyflutamide inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; hydroxyflutamide inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; hydroxyflutamide inhibits the reaction [Metribolone results in increased activity of AR protein]; hydroxyflutamide inhibits the reaction [Stanozolol binds to and results in increased activity of AR protein]; hydroxyflutamide inhibits the reaction [Testosterone binds to and results in increased activity of AR protein]; hydroxyflutamide inhibits the reaction [Testosterone results in increased phosphorylation of AR protein]; OSM protein promotes the reaction [hydroxyflutamide binds to and results in increased activity of AR protein] hydroxyflutamide affects the activity of AR protein hydroxyflutamide inhibits the reaction [Metribolone binds to AR protein] hydroxyflutamide analog binds to AR protein; hydroxyflutamide binds to AR protein hydroxyflutamide binds to and results in decreased activity of AR protein; hydroxyflutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of AR mRNA] |
CTD |
PMID:10053169 PMID:11751618 PMID:11861974 PMID:11861975 PMID:12114440 PMID:12730620 PMID:15056816 PMID:15084347 PMID:15994236 PMID:16934689 PMID:18275596 PMID:18324785 PMID:19672399 PMID:21295777 PMID:21506597 PMID:23146716 PMID:26485406 PMID:26602169 PMID:26778350 PMID:26867867 PMID:27473015 PMID:28009930 PMID:28163245 PMID:29392883 PMID:30247711 PMID:30582956 PMID:33049310 PMID:35344071 More...
|
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Avp |
arginine vasopressin |
affects expression |
EXP |
hydroxyflutamide affects the expression of AVP mRNA |
CTD |
PMID:20810896 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Cdh1 |
cadherin 1 |
increases phosphorylation multiple interactions |
ISO |
hydroxyflutamide results in increased phosphorylation of CDH1 protein 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [hydroxyflutamide results in increased phosphorylation of CDH1 protein] |
CTD |
PMID:28163245 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions decreases phosphorylation |
ISO |
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [hydroxyflutamide results in decreased phosphorylation of CDH2 protein]; wortmannin inhibits the reaction [hydroxyflutamide results in decreased phosphorylation of CDH2 protein] |
CTD |
PMID:28163245 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases phosphorylation multiple interactions |
ISO |
hydroxyflutamide results in decreased phosphorylation of CTNNB1 protein 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [hydroxyflutamide results in decreased phosphorylation of CTNNB1 protein]; wortmannin inhibits the reaction [hydroxyflutamide results in decreased phosphorylation of CTNNB1 protein] |
CTD |
PMID:28163245 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
ISO |
hydroxyflutamide results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:29556062 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression |
ISO |
hydroxyflutamide results in increased expression of CYP17A1 mRNA |
CTD |
PMID:29556062 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
hydroxyflutamide binds to and results in increased activity of ESR1 protein; hydroxyflutamide inhibits the reaction [[Dihydrotestosterone co-treated with Estradiol] results in decreased expression of ESR1 protein] |
CTD |
PMID:18275596 PMID:33049310 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
EXP |
[Testosterone co-treated with hydroxyflutamide] results in decreased expression of GJA1 protein; hydroxyflutamide results in decreased expression of and affects the localization of GJA1 protein; wortmannin inhibits the reaction [hydroxyflutamide results in decreased expression of GJA1 protein] |
CTD |
PMID:26437446 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
hydroxyflutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [BCG Vaccine results in increased expression of IL6 mRNA]] |
CTD |
PMID:14532843 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
affects secretion affects expression decreases expression increases secretion multiple interactions |
ISO |
hydroxyflutamide affects the secretion of KLK3 protein hydroxyflutamide affects the expression of KLK3 mRNA hydroxyflutamide results in decreased expression of KLK3 mRNA hydroxyflutamide results in increased secretion of KLK3 protein hydroxyflutamide inhibits the reaction [1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane results in increased expression of KLK3 protein]; hydroxyflutamide inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA]; hydroxyflutamide inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 protein]; hydroxyflutamide inhibits the reaction [Dihydrotestosterone results in increased secretion of KLK3 protein] |
CTD |
PMID:20363314 PMID:25454221 PMID:29556062 PMID:35595151 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Lcp1 |
lymphocyte cytosolic protein 1 |
decreases expression |
ISO |
hydroxyflutamide results in decreased expression of LCP1 mRNA |
CTD |
PMID:29556062 |
|
NCBI chr15:50,443,300...50,544,682
Ensembl chr15:50,488,149...50,544,680
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions affects phosphorylation increases phosphorylation |
EXP ISO |
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [hydroxyflutamide results in increased phosphorylation of MAPK1 protein]; hydroxyflutamide promotes the reaction [Testosterone results in increased phosphorylation of MAPK1 protein] hydroxyflutamide inhibits the reaction [Testosterone affects the phosphorylation of MAPK1 protein] hydroxyflutamide affects the phosphorylation of MAPK1 protein |
CTD |
PMID:26437446 PMID:28163245 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation affects phosphorylation multiple interactions |
EXP ISO |
hydroxyflutamide results in increased phosphorylation of MAPK3 protein hydroxyflutamide affects the phosphorylation of MAPK3 protein hydroxyflutamide inhibits the reaction [Testosterone affects the phosphorylation of MAPK3 protein] 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [hydroxyflutamide results in increased phosphorylation of MAPK3 protein]; hydroxyflutamide promotes the reaction [Testosterone results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:26437446 PMID:28163245 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Msmb |
microseminoprotein, beta |
decreases expression |
ISO |
hydroxyflutamide results in decreased expression of MSMB mRNA |
CTD |
PMID:29556062 |
|
NCBI chr16:7,366,536...7,387,124
Ensembl chr16:7,366,536...7,387,123
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
hydroxyflutamide binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Osm |
oncostatin M |
multiple interactions |
ISO |
OSM protein promotes the reaction [hydroxyflutamide binds to and results in increased activity of AR protein] |
CTD |
PMID:12114440 |
|
NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
|
|
G |
Pip |
prolactin induced protein |
multiple interactions decreases expression |
ISO |
hydroxyflutamide inhibits the reaction [Dihydrotestosterone results in increased expression of PIP mRNA] hydroxyflutamide results in decreased expression of PIP mRNA |
CTD |
PMID:10402478 |
|
NCBI chr 4:70,787,627...70,791,921
Ensembl chr 4:70,787,627...70,791,921
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
hydroxyflutamide binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Pten |
phosphatase and tensin homolog |
increases phosphorylation multiple interactions |
EXP |
hydroxyflutamide results in increased phosphorylation of PTEN protein hydroxyflutamide promotes the reaction [Testosterone results in increased phosphorylation of PTEN protein] |
CTD |
PMID:26437446 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions increases phosphorylation |
ISO |
wortmannin promotes the reaction [hydroxyflutamide results in increased phosphorylation of RAF1 protein] |
CTD |
PMID:28163245 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Sf1 |
splicing factor 1 |
decreases expression |
ISO |
hydroxyflutamide results in decreased expression of SF1 mRNA |
CTD |
PMID:29556062 |
|
NCBI chr 1:203,670,016...203,683,432
Ensembl chr 1:203,670,018...203,684,330
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
decreases phosphorylation multiple interactions |
EXP |
hydroxyflutamide results in decreased phosphorylation of SRC protein hydroxyflutamide inhibits the reaction [Testosterone results in increased phosphorylation of SRC protein] |
CTD |
PMID:26437446 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Srd5a1 |
steroid 5 alpha-reductase 1 |
decreases expression |
ISO |
hydroxyflutamide results in decreased expression of SRD5A1 mRNA |
CTD |
PMID:29556062 |
|
NCBI chr 1:33,686,069...33,720,468
Ensembl chr 1:33,686,391...33,720,461
|
|
G |
Srd5a2 |
steroid 5 alpha-reductase 2 |
multiple interactions |
ISO |
hydroxyflutamide inhibits the reaction [Dihydrotestosterone results in increased expression of SRD5A2 mRNA] |
CTD |
PMID:15056816 |
|
NCBI chr 6:21,426,225...21,465,727
Ensembl chr 6:21,426,215...21,462,112
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
hydroxyflutamide binds to and results in increased activity of THRA protein |
CTD |
PMID:33049310 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
hydroxyflutamide binds to and results in increased activity of THRB protein |
CTD |
PMID:33049310 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
|
G |
A1bg |
alpha-1-B glycoprotein |
increases expression |
ISO |
Niclosamide results in increased expression of A1BG mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 7:92,493,934...92,498,460
Ensembl chr 7:92,494,372...92,498,097
|
|
G |
Abca12 |
ATP binding cassette subfamily A member 12 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ABCA12 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 9:72,822,661...72,995,748
Ensembl chr 9:72,823,350...72,996,049
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ABCC9 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356
|
|
G |
Abcg4 |
ATP binding cassette subfamily G member 4 |
increases expression |
ISO |
Niclosamide results in increased expression of ABCG4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 8:44,611,187...44,629,818
Ensembl chr 8:44,611,187...44,626,881
|
|
G |
Abhd1 |
abhydrolase domain containing 1 |
increases expression |
ISO |
Niclosamide results in increased expression of ABHD1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 6:25,422,526...25,427,514
Ensembl chr 6:25,422,526...25,427,514
|
|
G |
Abhd14b |
abhydrolase domain containing 14b |
increases expression |
ISO |
Niclosamide results in increased expression of ABHD14B mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 8:107,087,157...107,092,122
Ensembl chr 8:107,088,069...107,092,119
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
decreases expression |
ISO |
Niclosamide results in decreased expression of ACACA mRNA |
CTD |
PMID:22576131 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of ACP5 mRNA] |
CTD |
PMID:26792726 PMID:28824321 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ACSL1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions decreases expression |
ISO |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of ACTA2 protein] Niclosamide results in decreased expression of ACTA2 protein Niclosamide results in decreased expression of ACTA2 mRNA; Niclosamide results in decreased expression of ACTA2 protein CTNNB1 protein inhibits the reaction [Niclosamide results in decreased expression of ACTA2 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of ACTA2 protein]; Niclosamide inhibits the reaction [TGFB1 protein results in increased phosphorylation of ACTA2 protein] |
CTD |
PMID:26643609 PMID:28318631 PMID:34118929 PMID:35115509 PMID:36870549 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adamts17 |
ADAM metallopeptidase with thrombospondin type 1 motif, 17 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ADAMTS17 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:120,445,800...120,768,204
Ensembl chr 1:120,445,749...120,768,202
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
decreases expression |
ISO |
Niclosamide results in decreased expression of ADH4 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Adm2 |
adrenomedullin 2 |
increases expression |
ISO |
Niclosamide results in increased expression of ADM2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 7:120,393,179...120,394,965
Ensembl chr 7:120,393,179...120,396,331
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
decreases expression |
ISO |
Niclosamide results in decreased expression of ADRA2A mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365
|
|
G |
Afp |
alpha-fetoprotein |
multiple interactions |
EXP |
Niclosamide inhibits the reaction [Thioacetamide results in increased expression of AFP protein]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of AFP protein]] |
CTD |
PMID:32961231 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Agbl3 |
AGBL carboxypeptidase 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of AGBL3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 4:63,448,789...63,535,538
Ensembl chr 4:63,453,940...63,531,188
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases cleavage |
ISO |
Niclosamide results in increased cleavage of AIFM1 protein |
CTD |
PMID:22576131 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akna |
AT-hook transcription factor |
increases expression |
ISO |
Niclosamide results in increased expression of AKNA mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:76,777,415...76,824,380
Ensembl chr 5:76,777,415...76,816,017
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases expression multiple interactions |
ISO |
Niclosamide results in increased expression of AKT1 mRNA Niclosamide inhibits the reaction [TNF protein results in increased activity of AKT1 protein]; Niclosamide inhibits the reaction [TNFSF11 protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:20215516 PMID:26792726 PMID:29843133 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ALDH1A1 protein |
CTD |
PMID:24736023 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh6a1 |
aldehyde dehydrogenase 6 family, member A1 |
increases expression |
ISO |
Niclosamide results in increased expression of ALDH6A1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656
|
|
G |
Aldob |
aldolase, fructose-bisphosphate B |
increases expression |
ISO |
Niclosamide results in increased expression of ALDOB mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 5:63,889,045...63,902,086
Ensembl chr 5:63,889,046...63,902,116
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
decreases expression increases expression |
ISO |
Niclosamide results in decreased expression of ALDOC mRNA Niclosamide results in increased expression of ALDOC mRNA |
CTD |
PMID:22576131 PMID:36318118 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alkbh7 |
alkB homolog 7 |
increases expression |
ISO |
Niclosamide results in increased expression of ALKBH7 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 9:1,838,886...1,841,044
Ensembl chr 9:1,838,811...1,841,044
|
|
G |
Alox12b |
arachidonate 12-lipoxygenase, 12R type |
increases expression multiple interactions decreases response to substance |
ISO |
Niclosamide results in increased expression of ALOX12B mRNA TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX12B mRNA]; TP53 protein mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX12B mRNA] ALOX12B protein results in decreased susceptibility to Niclosamide |
CTD |
PMID:30258081 |
|
NCBI chr10:53,863,060...53,874,938
Ensembl chr10:53,863,060...53,874,938
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions decreases response to substance increases expression |
ISO |
TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX5 mRNA]; TP53 protein mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX5 mRNA] ALOX5 protein results in decreased susceptibility to Niclosamide |
CTD |
PMID:30258081 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
decreases expression |
ISO |
Niclosamide results in decreased expression of ALPL mRNA |
CTD |
PMID:28824321 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Amhr2 |
anti-Mullerian hormone receptor type 2 |
increases expression |
ISO |
Niclosamide results in increased expression of AMHR2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 7:133,579,152...133,588,874
Ensembl chr 7:133,579,393...133,588,258
|
|
G |
Amot |
angiomotin |
increases expression |
ISO |
Niclosamide results in increased expression of AMOT mRNA |
CTD |
PMID:36318118 |
|
NCBI chr X:108,982,399...109,041,265
Ensembl chr X:108,984,022...109,041,272
|
|
G |
Ank3 |
ankyrin 3 |
increases expression |
ISO |
Niclosamide results in increased expression of ANK3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr20:18,602,267...19,225,831
Ensembl chr20:18,602,786...19,086,300
|
|
G |
Ankmy2 |
ankyrin repeat and MYND domain containing 2 |
increases expression |
ISO |
Niclosamide results in increased expression of ANKMY2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 6:52,888,959...52,930,343
Ensembl chr 6:52,888,963...52,930,394
|
|
G |
Ankrd12 |
ankyrin repeat domain 12 |
increases expression |
ISO |
Niclosamide results in increased expression of ANKRD12 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 9:105,583,273...105,687,957
Ensembl chr 9:105,584,065...105,687,911
|
|
G |
Ankrd34a |
ankyrin repeat domain 34A |
increases expression |
ISO |
Niclosamide results in increased expression of ANKRD34A mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 2:184,129,830...184,135,075
Ensembl chr 2:184,129,238...184,135,116
|
|
G |
Anxa4 |
annexin A4 |
increases expression |
ISO |
Niclosamide results in increased expression of ANXA4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Ap1s3 |
adaptor related protein complex 1 subunit sigma 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of AP1S3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 9:80,950,402...81,009,889
Ensembl chr 9:80,950,715...81,009,798
|
|
G |
Aplnr |
apelin receptor |
decreases expression |
ISO |
Niclosamide results in decreased expression of APLNR mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 3:70,217,407...70,221,052
Ensembl chr 3:70,217,385...70,221,050
|
|
G |
Apof |
apolipoprotein F |
decreases expression |
ISO |
Niclosamide results in decreased expression of APOF mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 7:700,688...702,130
Ensembl chr 7:700,762...701,946
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases expression |
ISO |
[enzalutamide co-treated with Niclosamide] results in decreased expression of AR protein; [Niclosamide inhibits the reaction [AR protein binds to KLK3 promoter]] which results in decreased expression of KLK3 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Niclosamide results in decreased expression of and results in increased degradation of AR protein alternative form]; bicalutamide promotes the reaction [Niclosamide inhibits the reaction [AR protein binds to KLK3 promoter]]; bicalutamide promotes the reaction [Niclosamide results in decreased expression of AR protein alternative form]; bicalutamide promotes the reaction [Niclosamide results in decreased expression of AR protein]; Niclosamide inhibits the reaction [AR protein alternative form binds to KLK3 promoter]; Niclosamide inhibits the reaction [AR protein alternative form results in decreased susceptibility to enzalutamide]; Niclosamide inhibits the reaction [AR protein alternative form results in increased expression of KLK3 mRNA]; Niclosamide inhibits the reaction [AR protein alternative form results in increased expression of KLK3 protein]; Niclosamide inhibits the reaction [AR protein binds to KLK3 promoter]; Niclosamide inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; Niclosamide results in decreased expression of and results in increased degradation of AR protein alternative form Niclosamide results in decreased expression of AR protein; Niclosamide results in decreased expression of AR protein alternative form |
CTD |
PMID:24740322 PMID:25970160 PMID:28500234 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Araf |
A-Raf proto-oncogene, serine/threonine kinase |
decreases expression |
ISO |
Niclosamide analog results in decreased expression of ARAF protein; Niclosamide results in decreased expression of ARAF protein |
CTD |
PMID:28284560 |
|
NCBI chr X:1,227,392...1,292,356
Ensembl chr X:1,227,392...1,239,073
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
increases expression |
ISO |
Niclosamide results in increased expression of ARHGDIB mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658
|
|
G |
Armcx1 |
armadillo repeat containing, X-linked 1 |
increases expression |
ISO |
Niclosamide results in increased expression of ARMCX1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr X:97,898,969...97,902,874
Ensembl chr X:97,898,883...97,903,299
|
|
G |
Arrdc2 |
arrestin domain containing 2 |
increases expression |
ISO |
Niclosamide results in increased expression of ARRDC2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr16:18,601,897...18,606,029
Ensembl chr16:18,601,897...18,606,029
|
|
G |
Asf1b |
anti-silencing function 1B histone chaperone |
decreases expression |
ISO |
Niclosamide results in decreased expression of ASF1B mRNA |
CTD |
PMID:28284560 |
|
NCBI chr19:24,181,024...24,195,604
Ensembl chr19:24,181,028...24,195,549
|
|
G |
Atcay |
ATCAY kinesin light chain interacting caytaxin |
increases expression |
ISO |
Niclosamide results in increased expression of ATCAY mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 7:8,487,763...8,511,527
Ensembl chr 7:8,487,763...8,512,663
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression multiple interactions |
ISO |
Niclosamide results in increased expression of ATF3 mRNA; Niclosamide results in increased expression of ATF3 protein ATF3 protein affects the reaction [Niclosamide results in increased cleavage of CASP3 protein]; ATF3 protein affects the reaction [Niclosamide results in increased expression of DDIT3 mRNA]; ATF3 protein affects the reaction [Niclosamide results in increased expression of EIF2AK3 mRNA] |
CTD |
PMID:26917416 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
Niclosamide results in increased expression of ATF4 mRNA; Niclosamide results in increased expression of ATF4 protein |
CTD |
PMID:26917416 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atosb |
atos homolog B |
increases expression |
ISO |
Niclosamide results in increased expression of ATOSB mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:57,260,839...57,274,524
Ensembl chr 5:57,260,841...57,268,892
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
increases expression |
ISO |
Niclosamide results in increased expression of ATP2A3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
increases expression |
ISO |
Niclosamide results in increased expression of ATP5F1A mRNA |
CTD |
PMID:22576131 |
|
NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
|
|
G |
Atp5f1d |
ATP synthase F1 subunit delta |
increases expression |
ISO |
Niclosamide results in increased expression of ATP5F1D mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 7:9,560,604...9,565,919
Ensembl chr 7:9,560,608...9,565,929
|
|
G |
Atp5mc3 |
ATP synthase membrane subunit c locus 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ATP5MC3 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 3:58,810,535...58,813,185
Ensembl chr 3:58,810,535...58,814,279
|
|
G |
Atp5mf |
ATP synthase membrane subunit f |
decreases expression |
ISO |
Niclosamide results in decreased expression of ATP5MF mRNA |
CTD |
PMID:22576131 |
|
NCBI chr12:9,421,665...9,428,236
Ensembl chr12:9,421,579...9,428,236
|
|
G |
Atp5mg |
ATP synthase membrane subunit G |
decreases expression |
ISO |
Niclosamide results in decreased expression of ATP5MG mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 8:45,225,680...45,233,630
Ensembl chr 8:45,225,686...45,233,559
|
|
G |
Atp5pb |
ATP synthase peripheral stalk-membrane subunit b |
decreases expression |
ISO |
Niclosamide results in decreased expression of ATP5PB mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 2:193,424,138...193,435,418
Ensembl chr 2:193,424,047...193,435,418
|
|
G |
Atp6ap1 |
ATPase H+ transporting accessory protein 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ATP6AP1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr X:152,079,954...152,087,034
Ensembl chr X:152,079,865...152,087,034
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of ATP6V0D2 mRNA] |
CTD |
PMID:26792726 |
|
NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354
|
|
G |
Atpsckmt |
ATP synthase c subunit lysine N-methyltransferase |
decreases expression |
ISO |
Niclosamide results in decreased expression of ATPSCKMT mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 2:82,603,086...82,618,325
Ensembl chr 2:82,603,009...82,618,308
|
|
G |
Aurkb |
aurora kinase B |
decreases expression |
ISO |
Niclosamide results in decreased expression of AURKB mRNA |
CTD |
PMID:28284560 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Avpi1 |
arginine vasopressin-induced 1 |
increases expression |
ISO |
Niclosamide results in increased expression of AVPI1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:240,930,236...240,936,154
Ensembl chr 1:240,930,236...240,936,154
|
|
G |
Axin2 |
axin 2 |
multiple interactions decreases expression |
ISO |
Niclosamide inhibits the reaction [Lithium Chloride results in increased expression of AXIN2 mRNA] Niclosamide results in decreased expression of AXIN2 mRNA; Niclosamide results in decreased expression of AXIN2 protein |
CTD |
PMID:22576131 PMID:24534281 PMID:24552774 PMID:24736023 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
B3gnt7 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 |
increases expression |
ISO |
Niclosamide results in increased expression of B3GNT7 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 9:86,956,220...86,960,171
Ensembl chr 9:86,956,220...86,960,170
|
|
G |
B3gnt9 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9 |
increases expression |
ISO |
Niclosamide results in increased expression of B3GNT9 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr19:33,129,740...33,134,048
Ensembl chr19:33,128,142...33,132,344
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
[Niclosamide binds to Polyethyleneimine] which results in increased expression of BAD mRNA |
CTD |
PMID:25988281 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
ISO |
[Niclosamide binds to Polyethyleneimine] which results in increased expression of BAK1 mRNA |
CTD |
PMID:25988281 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions decreases expression |
ISO |
Niclosamide results in increased expression of BAX protein [Niclosamide binds to Polyethyleneimine] which results in increased expression of BAX mRNA; [Niclosamide co-treated with bicalutamide] results in increased expression of BAX protein; bicalutamide inhibits the reaction [Niclosamide results in decreased expression of BAX protein] |
CTD |
PMID:25634333 PMID:25988281 PMID:26703449 PMID:28500234 PMID:35115509 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions increases expression |
ISO |
TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of BBC3 mRNA] |
CTD |
PMID:30258081 PMID:36318118 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bbs2 |
Bardet-Biedl syndrome 2 |
increases expression |
ISO |
Niclosamide results in increased expression of BBS2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr19:10,909,653...10,944,998
Ensembl chr19:10,909,619...10,944,993
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO |
Niclosamide analog results in decreased expression of BCL2 protein; Niclosamide results in decreased expression of BCL2 protein [Niclosamide binds to Polyethyleneimine] which results in decreased expression of BCL2 mRNA; [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; bicalutamide promotes the reaction [Niclosamide results in decreased expression of BCL2 protein]; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]; Niclosamide inhibits the reaction [TNF protein results in increased expression of BCL2 mRNA]; Niclosamide promotes the reaction [bicalutamide results in decreased expression of BCL2 protein] |
CTD |
PMID:20215516 PMID:23894143 PMID:25634333 PMID:25988281 PMID:26116531 PMID:26703449 PMID:28284560 PMID:28500234 PMID:35115509 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression |
ISO |
[Niclosamide binds to Polyethyleneimine] which results in decreased expression of BCL2L1 mRNA; bicalutamide promotes the reaction [Niclosamide results in decreased expression of BCL2L1 protein]; Niclosamide inhibits the reaction [TNF protein results in increased expression of BCL2L1 mRNA]; Niclosamide promotes the reaction [bicalutamide results in decreased expression of BCL2L1 protein] Niclosamide analog results in decreased expression of BCL2L1 protein; Niclosamide results in decreased expression of BCL2L1 protein |
CTD |
PMID:20215516 PMID:25988281 PMID:26116531 PMID:28284560 PMID:28500234 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
decreases expression multiple interactions |
ISO |
Niclosamide results in decreased expression of BCL2L2 protein [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein] |
CTD |
PMID:23894143 |
|
NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624
|
|
G |
Bcl3 |
BCL3, transcription coactivator |
increases expression |
ISO |
Niclosamide results in increased expression of BCL3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607
|
|
G |
Bcl6 |
BCL6, transcription repressor |
multiple interactions increases expression |
ISO |
Niclosamide affects the reaction [FAS protein mutant form affects the expression of BCL6 mRNA]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of BCL6 protein] Niclosamide results in increased expression of BCL6 mRNA |
CTD |
PMID:33632240 PMID:36318118 |
|
NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
|
|
G |
Bcl6b |
BCL6B, transcription repressor |
increases expression |
ISO |
Niclosamide results in increased expression of BCL6B mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:54,940,908...54,947,022
Ensembl chr10:54,940,909...54,945,974
|
|
G |
Bcl9 |
BCL9, transcription coactivator |
decreases expression |
EXP |
Niclosamide results in decreased expression of BCL9 mRNA |
CTD |
PMID:27338550 |
|
NCBI chr 2:184,760,616...184,846,261
Ensembl chr 2:184,760,618...184,786,435
|
|
G |
Bcorl1 |
BCL6 co-repressor-like 1 |
increases expression |
ISO |
Niclosamide results in increased expression of BCORL1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr X:127,516,504...127,584,529
Ensembl chr X:127,537,538...127,584,087
|
|
G |
Bet1l |
Bet1 golgi vesicular membrane trafficking protein-like |
increases expression |
ISO |
Niclosamide results in increased expression of BET1L mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:195,931,407...195,935,072
Ensembl chr 1:195,931,411...195,935,040
|
|
G |
Bgn |
biglycan |
increases expression |
ISO |
Niclosamide results in increased expression of BGN mRNA |
CTD |
PMID:36318118 |
|
NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
increases expression |
ISO |
Niclosamide results in increased expression of BHLHE40 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions affects expression decreases expression |
ISO |
enzalutamide promotes the reaction [Niclosamide results in decreased expression of BIRC5 protein]; Niclosamide inhibits the reaction [IL6 protein results in increased expression of BIRC5 protein] Niclosamide affects the expression of BIRC5 protein Niclosamide analog results in decreased expression of BIRC5 protein; Niclosamide results in decreased expression of BIRC5 mRNA; Niclosamide results in decreased expression of BIRC5 protein |
CTD |
PMID:24552774 PMID:24736023 PMID:25970160 PMID:28284560 PMID:28500234 PMID:36318118 More...
|
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmf |
Bcl2 modifying factor |
increases expression |
ISO |
Niclosamide results in increased expression of BMF mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145
|
|
G |
Borcs6 |
BLOC-1 related complex subunit 6 |
increases expression |
ISO |
Niclosamide results in increased expression of BORCS6 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:53,760,504...53,762,358
Ensembl chr10:53,758,093...53,762,632
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
decreases expression decreases phosphorylation |
ISO |
Niclosamide analog results in decreased expression of BRAF protein; Niclosamide results in decreased expression of BRAF protein Niclosamide analog results in decreased phosphorylation of BRAF protein |
CTD |
PMID:28284560 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
Btbd7 |
BTB domain containing 7 |
decreases expression |
ISO |
Niclosamide results in decreased expression of BTBD7 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 6:121,920,365...122,010,114
Ensembl chr 6:121,923,023...121,972,405
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
Niclosamide results in increased expression of BTG2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
C13h1orf105 |
similar to human chromosome 1 open reading frame 105 |
decreases expression |
ISO |
Niclosamide results in decreased expression of C1ORF105 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr13:74,313,320...74,356,322
Ensembl chr13:74,313,322...74,356,322
|
|
G |
C16h8orf48 |
similar to human chromosome 8 open reading frame 48 |
decreases expression |
ISO |
Niclosamide results in decreased expression of C8ORF48 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr16:55,244,744...55,246,642
Ensembl chr16:55,236,322...55,246,650
|
|
G |
C19h16orf86 |
similar to human chromosome 16 open reading frame 86 |
increases expression |
ISO |
Niclosamide results in increased expression of C16ORF86 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr19:33,596,591...33,598,703
Ensembl chr19:33,595,995...33,598,521
|
|
G |
C1ql4 |
complement C1q like 4 |
increases expression |
ISO |
Niclosamide results in increased expression of C1QL4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 7:130,243,606...130,246,678
Ensembl chr 7:130,243,606...130,246,678
|
|
G |
Cables2 |
Cdk5 and Abl enzyme substrate 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CABLES2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 3:167,347,527...167,362,274
Ensembl chr 3:167,347,461...167,362,279
|
|
G |
Cacna1e |
calcium voltage-gated channel subunit alpha1 E |
increases expression |
ISO |
Niclosamide results in increased expression of CACNA1E mRNA |
CTD |
PMID:36318118 |
|
NCBI chr13:66,574,659...67,063,443
Ensembl chr13:66,581,920...66,894,450
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
increases expression |
ISO |
Niclosamide results in increased expression of CACNA1H mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376
|
|
G |
Cacng1 |
calcium voltage-gated channel auxiliary subunit gamma 1 |
increases expression |
ISO |
Niclosamide results in increased expression of CACNG1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:92,652,924...92,665,612
Ensembl chr10:92,652,614...92,665,783
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
increases expression |
ISO |
Niclosamide results in increased expression of CAMK2A mRNA |
CTD |
PMID:36318118 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Camsap3 |
calmodulin regulated spectrin-associated protein family, member 3 |
increases expression |
ISO |
Niclosamide results in increased expression of CAMSAP3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr12:1,643,062...1,666,685
Ensembl chr12:1,643,251...1,666,685
|
|
G |
Caps |
calcyphosine |
increases expression |
ISO |
Niclosamide results in increased expression of CAPS mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 9:1,544,597...1,545,631
Ensembl chr 9:1,544,719...1,545,647
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
[Niclosamide co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CASP1 protein Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein] |
CTD |
PMID:33524445 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases expression decreases expression |
ISO EXP |
Niclosamide results in increased cleavage of CASP3 protein Niclosamide inhibits the reaction [Thioacetamide results in decreased expression of CASP3 mRNA]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in decreased expression of CASP3 mRNA]] [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased expression of CASP3 protein modified form; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 protein modified form] Niclosamide results in increased expression of CASP3 protein modified form Niclosamide results in decreased expression of CASP3 protein 7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine inhibits the reaction [Niclosamide results in increased cleavage of CASP3 protein]; [Niclosamide binds to Polyethyleneimine] which results in increased expression of CASP3 mRNA; ATF3 protein affects the reaction [Niclosamide results in increased cleavage of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [Niclosamide results in increased cleavage of CASP3 protein]; TP53 gene mutant form promotes the reaction [Niclosamide results in increased cleavage of CASP3 protein]; WNT7A protein affects the reaction [Niclosamide results in increased cleavage of CASP3 protein] |
CTD |
PMID:20215516 PMID:21871175 PMID:24750999 PMID:25174399 PMID:25634333 PMID:25988281 PMID:26116531 PMID:26703449 PMID:26917416 PMID:28824321 PMID:29031202 PMID:30258081 PMID:30329025 PMID:32961231 PMID:35115509 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases expression |
ISO |
bicalutamide promotes the reaction [Niclosamide results in increased expression of CASP7 protein modified form] |
CTD |
PMID:26116531 PMID:28500234 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases cleavage |
ISO |
Niclosamide results in increased cleavage of CASP8 protein |
CTD |
PMID:35115509 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression increases cleavage |
ISO |
TP53 gene mutant form promotes the reaction [Niclosamide results in increased cleavage of CASP9 protein] Niclosamide results in increased expression of CASP9 mRNA; Niclosamide results in increased expression of CASP9 protein modified form |
CTD |
PMID:26116531 PMID:26703449 PMID:30258081 PMID:36318118 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cbx4 |
chromobox 4 |
increases expression |
ISO |
Niclosamide results in increased expression of CBX4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:104,337,140...104,343,210
Ensembl chr10:104,336,876...104,356,706
|
|
G |
Ccdc113 |
coiled-coil domain containing 113 |
increases expression |
ISO |
Niclosamide results in increased expression of CFAP263 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr19:9,497,000...9,516,917
Ensembl chr19:9,496,886...9,516,923
|
|
G |
Ccdc188 |
coiled-coil domain containing 188 |
increases expression |
ISO |
Niclosamide results in increased expression of CCDC188 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr11:82,769,735...82,772,062
Ensembl chr11:82,769,473...82,772,114
|
|
G |
Ccdc68 |
coiled-coil domain containing 68 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CCDC68 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr18:63,541,828...63,584,122
Ensembl chr18:63,541,896...63,584,119
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of CCL2 mRNA]; Niclosamide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of CCL2 mRNA] |
CTD |
PMID:24561310 PMID:28318631 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions |
ISO EXP |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of CCL20 mRNA] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of CCL20 mRNA] |
CTD |
PMID:28318631 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein] |
CTD |
PMID:24561310 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL5 protein] |
CTD |
PMID:24561310 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CCNB1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnb3 |
cyclin B3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CCNB3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr X:15,478,050...15,543,292
Ensembl chr X:15,478,065...15,542,885
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
EXP ISO |
Niclosamide inhibits the reaction [Epinephrine results in increased expression of CCND1 mRNA]; Niclosamide inhibits the reaction [GCG protein results in increased expression of CCND1 mRNA]; Niclosamide inhibits the reaction [GCG protein results in increased expression of CCND1 protein]; Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CCND1 mRNA]; Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CCND1 protein]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CCND1 mRNA]]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CCND1 protein]] Niclosamide results in decreased expression of CCND1 mRNA Niclosamide analog results in decreased expression of CCND1 protein; Niclosamide results in decreased expression of CCND1 mRNA; Niclosamide results in decreased expression of CCND1 protein Niclosamide inhibits the reaction [IL6 protein results in increased expression of CCND1 mRNA]; Niclosamide inhibits the reaction [TNF protein results in increased expression of CCND1 mRNA]; Niclosamide promotes the reaction [bicalutamide results in decreased expression of CCND1 protein] |
CTD |
PMID:19160421 PMID:20215516 PMID:24552774 PMID:24736023 PMID:26297436 PMID:26964897 PMID:27338550 PMID:28284560 PMID:28500234 PMID:30143678 PMID:32961231 PMID:36318118 More...
|
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression increases expression |
ISO |
Niclosamide results in decreased expression of CCND2 mRNA Niclosamide results in increased expression of CCND2 mRNA |
CTD |
PMID:22576131 PMID:27226553 PMID:36318118 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CCND3 mRNA |
CTD |
PMID:22576131 PMID:27226553 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CCNE1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccne2 |
cyclin E2 |
multiple interactions decreases expression |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in increased expression of CCNE2 mRNA] Niclosamide results in decreased expression of CCNE2 mRNA |
CTD |
PMID:27542212 PMID:36318118 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Ccng2 |
cyclin G2 |
multiple interactions increases expression |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of CCNG2 mRNA] Niclosamide results in increased expression of CCNG2 mRNA |
CTD |
PMID:27542212 PMID:36318118 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Ccr10 |
C-C motif chemokine receptor 10 |
increases expression |
ISO |
Niclosamide results in increased expression of CCR10 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:86,108,551...86,110,988
Ensembl chr10:86,108,551...86,110,988
|
|
G |
Cd27 |
CD27 molecule |
increases expression |
ISO |
Niclosamide results in increased expression of CD27 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 4:158,030,700...158,035,862
Ensembl chr 4:158,030,703...158,035,592
|
|
G |
Cd274 |
CD274 molecule |
decreases expression |
ISO |
Niclosamide results in decreased expression of CD274 mRNA; Niclosamide results in decreased expression of CD274 protein |
CTD |
PMID:35115509 |
|
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Lipopolysaccharides affects the expression of CD40 protein] |
CTD |
PMID:24561310 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
increases expression |
ISO |
Niclosamide results in increased expression of CD55 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831
|
|
G |
Cd68 |
Cd68 molecule |
increases expression |
ISO |
Niclosamide results in increased expression of CD68 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Lipopolysaccharides affects the expression of CD80 protein] |
CTD |
PMID:24561310 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Lipopolysaccharides affects the expression of CD86 protein] |
CTD |
PMID:24561310 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdc37 |
cell division cycle 37, HSP90 cochaperone |
multiple interactions |
ISO |
CDC37 protein binds to and results in increased susceptibility to Niclosamide analog |
CTD |
PMID:28284560 |
|
NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases expression decreases phosphorylation |
ISO |
Niclosamide results in decreased expression of CDC42 mRNA Niclosamide results in decreased phosphorylation of CDC42 protein |
CTD |
PMID:29251334 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdc42ep1 |
CDC42 effector protein 1 |
increases expression |
ISO |
Niclosamide results in increased expression of CDC42EP1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 7:110,395,287...110,403,203
Ensembl chr 7:110,395,332...110,403,200
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDC6 mRNA |
CTD |
PMID:28284560 PMID:36318118 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdca2 |
cell division cycle associated 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDCA2 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr15:41,895,946...41,942,226
Ensembl chr15:41,895,901...41,941,611
|
|
G |
Cdca5 |
cell division cycle associated 5 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDCA5 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 1:203,378,550...203,392,027
Ensembl chr 1:203,378,577...203,392,023
|
|
G |
Cdca8 |
cell division cycle associated 8 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDCA8 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions increases expression |
ISO |
CTNNB1 protein inhibits the reaction [Niclosamide results in increased expression of CDH1 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein]; WNT7A protein affects the reaction [Niclosamide results in increased expression of CDH1 protein] Niclosamide results in increased expression of CDH1 mRNA; Niclosamide results in increased expression of CDH1 protein |
CTD |
PMID:25174399 PMID:26643609 PMID:30143678 PMID:35115509 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh11 |
cadherin 11 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDH11 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr19:2,148,447...2,305,754
Ensembl chr19:2,148,458...2,304,272
|
|
G |
Cdh12 |
cadherin 12 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of CDH12 protein] |
CTD |
PMID:36870549 |
|
NCBI chr 2:70,474,679...71,705,369
Ensembl chr 2:70,475,043...71,700,572
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions decreases expression |
ISO |
Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of CDH2 protein] Niclosamide results in decreased expression of CDH2 protein |
CTD |
PMID:26643609 PMID:34118929 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdh4 |
cadherin 4 |
increases expression |
ISO |
Niclosamide results in increased expression of CDH4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 3:166,525,092...167,003,380
Ensembl chr 3:166,525,099...167,003,371
|
|
G |
Cdh6 |
cadherin 6 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDH6 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 2:62,079,139...62,225,298
Ensembl chr 2:62,079,137...62,225,228
|
|
G |
Cdhr1 |
cadherin-related family member 1 |
increases expression |
ISO |
Niclosamide results in increased expression of CDHR1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr16:12,843,436...12,863,321
Ensembl chr16:12,843,437...12,863,396
|
|
G |
Cdhr2 |
cadherin-related family member 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDHR2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr17:9,876,853...9,913,356
Ensembl chr17:9,876,860...9,912,575
|
|
G |
Cdk15 |
cyclin-dependent kinase 15 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDK15 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 9:60,710,787...60,803,638
Ensembl chr 9:60,711,715...60,802,777
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDK2 protein |
CTD |
PMID:29031202 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDK4 protein |
CTD |
PMID:29031202 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkl3 |
cyclin-dependent kinase-like 3 |
increases expression |
ISO |
Niclosamide results in increased expression of CDKL3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:36,263,212...36,349,268
Ensembl chr10:36,266,977...36,349,268
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of CDKN1A mRNA]; TP53 protein mutant form inhibits the reaction [Niclosamide results in increased expression of CDKN1A mRNA] |
CTD |
PMID:30258081 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDKN3 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression |
ISO |
Niclosamide results in increased expression of CEBPB mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Celf6 |
CUGBP, Elav-like family member 6 |
increases expression |
ISO |
Niclosamide results in increased expression of CELF6 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 8:59,975,095...60,006,060
Ensembl chr 8:59,975,088...60,005,041
|
|
G |
Celsr3 |
cadherin, EGF LAG seven-pass G-type receptor 3 |
increases expression |
ISO |
Niclosamide results in increased expression of CELSR3 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 8:109,530,597...109,558,360
Ensembl chr 8:109,530,641...109,558,354
|
|
G |
Cenpa |
centromere protein A |
decreases expression |
ISO |
Niclosamide results in decreased expression of CENPA mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675
|
|
G |
Cenpo |
centromere protein O |
decreases expression |
ISO |
Niclosamide results in decreased expression of CENPO mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 6:27,203,642...27,218,394
Ensembl chr 6:27,188,537...27,218,314
|
|
G |
Cenpu |
centromere protein U |
decreases expression |
ISO |
Niclosamide results in decreased expression of CENPU mRNA |
CTD |
PMID:36318118 |
|
NCBI chr16:45,715,821...45,739,038
Ensembl chr16:45,714,294...45,738,823
|
|
G |
Cfap70 |
cilia and flagella associated protein 70 |
increases expression |
ISO |
Niclosamide results in increased expression of CFAP70 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr15:3,852,381...3,918,036
Ensembl chr15:3,852,509...3,918,014
|
|
G |
Cfp |
complement factor properdin |
increases expression |
ISO |
Niclosamide results in increased expression of CFP mRNA |
CTD |
PMID:28284560 |
|
NCBI chr X:1,162,014...1,167,576
Ensembl chr X:1,161,979...1,167,573
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
increases expression |
ISO |
Niclosamide results in increased expression of CHAC1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Chac2 |
ChaC glutathione specific gamma-glutamylcyclotransferase 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CHAC2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr14:104,720,754...104,728,305
Ensembl chr14:104,720,758...104,728,301
|
|
G |
Chaf1a |
chromatin assembly factor 1 subunit A |
decreases expression |
ISO |
Niclosamide results in decreased expression of CHAF1A mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654
|
|
G |
Chrnb1 |
cholinergic receptor nicotinic beta 1 subunit |
increases expression |
ISO |
Niclosamide results in increased expression of CHRNB1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:54,501,096...54,516,418
Ensembl chr10:54,501,093...54,516,345
|
|
G |
Chst8 |
carbohydrate sulfotransferase 8 |
increases expression |
ISO |
Niclosamide results in increased expression of CHST8 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:87,294,144...87,435,900
Ensembl chr 1:87,294,540...87,435,900
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
Niclosamide results in decreased phosphorylation of and affects the localization of CHUK protein |
CTD |
PMID:26116531 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cish |
cytokine inducible SH2-containing protein |
increases expression |
ISO |
Niclosamide results in increased expression of CISH mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 8:107,972,306...107,977,254
Ensembl chr 8:107,972,306...107,977,250
|
|
G |
Clec11a |
C-type lectin domain containing 11A |
increases expression |
ISO |
Niclosamide results in increased expression of CLEC11A mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:94,800,456...94,809,002
Ensembl chr 1:94,801,496...94,804,633
|
|
G |
Clip2 |
CAP-GLY domain containing linker protein 2 |
increases expression |
ISO |
Niclosamide results in increased expression of CLIP2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr12:22,163,044...22,227,023
Ensembl chr12:22,163,218...22,227,023
|
|
G |
Clip3 |
CAP-GLY domain containing linker protein 3 |
increases expression |
ISO |
Niclosamide results in increased expression of CLIP3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:85,547,170...85,563,187
Ensembl chr 1:85,547,206...85,563,184
|
|
G |
Clspn |
claspin |
decreases expression |
ISO |
Niclosamide results in decreased expression of CLSPN mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:138,850,119...138,885,037
Ensembl chr 5:138,850,128...138,885,034
|
|
G |
Clstn3 |
calsyntenin 3 |
increases expression |
ISO |
Niclosamide results in increased expression of CLSTN3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769
|
|
G |
Cmklr1 |
chemerin chemokine-like receptor 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CMKLR1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr12:42,974,462...43,027,321
Ensembl chr12:42,974,410...43,028,129
|
|
G |
Cmpk2 |
cytidine/uridine monophosphate kinase 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CMPK2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 6:43,073,706...43,085,183
Ensembl chr 6:43,073,796...43,085,183
|
|
G |
Cnbd2 |
cyclic nucleotide binding domain containing 2 |
increases expression |
ISO |
Niclosamide results in increased expression of CNBD2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 3:144,819,166...144,884,825
Ensembl chr 3:144,819,195...144,901,583
|
|
G |
Cnn1 |
calponin 1 |
increases expression |
ISO |
Niclosamide results in increased expression of CNN1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 8:20,632,434...20,641,097
Ensembl chr 8:20,632,338...20,641,098
|
|
G |
Cnn2 |
calponin 2 |
increases expression |
ISO |
Niclosamide results in increased expression of CNN2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 7:9,712,505...9,719,678
Ensembl chr 7:9,712,516...9,719,656
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression multiple interactions |
ISO |
Niclosamide results in decreased expression of COL1A1 mRNA CTNNB1 protein inhibits the reaction [Niclosamide results in decreased expression of COL1A1 protein]; Gemcitabine inhibits the reaction [Niclosamide results in decreased expression of COL1A1 protein]; Niclosamide inhibits the reaction [Gemcitabine results in decreased expression of COL1A1 protein] |
CTD |
PMID:28824321 PMID:35115509 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col6a2 |
collagen type VI alpha 2 chain |
increases expression |
ISO |
Niclosamide results in increased expression of COL6A2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564
|
|
G |
Colec10 |
collectin subfamily member 10 |
increases expression |
ISO |
Niclosamide results in increased expression of COLEC10 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 7:85,744,895...85,806,368
Ensembl chr 7:85,744,895...85,805,675
|
|
G |
Cox8c |
cytochrome c oxidase subunit 8C |
increases expression |
ISO |
Niclosamide results in increased expression of COX8C mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 6:122,028,566...122,029,889
Ensembl chr 6:122,028,566...122,029,889
|
|
G |
Crb2 |
crumbs cell polarity complex component 2 |
increases expression |
ISO |
Niclosamide results in increased expression of CRB2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 3:21,542,138...21,564,876
Ensembl chr 3:21,542,221...21,563,294
|
|
G |
Crebbp |
CREB binding protein |
increases expression |
ISO |
Niclosamide results in increased expression of CREBBP mRNA |
CTD |
PMID:22576131 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Crebrf |
CREB3 regulatory factor |
increases expression |
ISO |
Niclosamide results in increased expression of CREBRF mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:16,399,170...16,479,650
Ensembl chr10:16,404,596...16,461,999
|
|
G |
Crlf1 |
cytokine receptor-like factor 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CRLF1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr16:18,924,722...18,936,049
Ensembl chr16:18,924,722...18,935,997
|
|
G |
Crot |
carnitine O-octanoyltransferase |
decreases expression |
ISO |
Niclosamide results in decreased expression of CROT mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109
|
|
G |
Crybb1 |
crystallin, beta B1 |
increases expression |
ISO |
Niclosamide results in increased expression of CRYBB1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr12:44,369,734...44,383,344
Ensembl chr12:44,369,735...44,383,344
|
|
G |
Cryl1 |
crystallin, lambda 1 |
increases expression |
ISO |
Niclosamide results in increased expression of CRYL1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr15:31,427,011...31,545,997
Ensembl chr15:31,427,054...31,545,997
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of ACP5 mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of and affects the localization of NFATC1 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 protein modified form]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of FOS mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of ITGB3 mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of MMP9 mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of NFATC1 mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of OCSTAMP mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of OSCAR mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of TRAF6 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK1 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK3 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK8 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK9 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of NFKBIA protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of RELA protein] |
CTD |
PMID:28824321 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csgalnact1 |
chondroitin sulfate N-acetylgalactosaminyltransferase 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of CSGALNACT1 mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr16:20,995,210...21,330,586
Ensembl chr16:21,235,784...21,330,319
|
|
G |
Csnk1e |
casein kinase 1, epsilon |
increases expression |
ISO |
Niclosamide results in increased expression of CSNK1E mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 7:110,983,322...111,006,926
Ensembl chr 7:110,983,318...111,006,794
|
|
G |
Csrnp1 |
cysteine and serine rich nuclear protein 1 |
increases expression |
ISO |
Niclosamide results in increased expression of CSRNP1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183
|
|
G |
Ctbp1 |
C-terminal binding protein 1 |
increases expression |
ISO |
Niclosamide results in increased expression of CTBP1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr14:77,455,580...77,482,821
Ensembl chr14:77,455,696...77,482,821
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression affects localization decreases expression increases ubiquitination decreases activity multiple interactions |
ISO EXP |
Niclosamide results in increased expression of CTNNB1 mRNA Niclosamide affects the localization of CTNNB1 protein Niclosamide results in decreased expression of CTNNB1 mRNA Niclosamide results in increased ubiquitination of CTNNB1 protein Niclosamide results in decreased activity of CTNNB1 protein Niclosamide inhibits the reaction [Epinephrine results in increased phosphorylation of CTNNB1 protein]; Niclosamide inhibits the reaction [GCG protein results in increased phosphorylation of CTNNB1 protein]; Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CTNNB1 protein]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CTNNB1 protein]] Niclosamide analog results in decreased expression of CTNNB1 protein; Niclosamide results in decreased expression of CTNNB1 protein CTNNB1 protein inhibits the reaction [Niclosamide results in decreased expression of ACTA2 protein]; CTNNB1 protein inhibits the reaction [Niclosamide results in decreased expression of COL1A1 protein]; CTNNB1 protein inhibits the reaction [Niclosamide results in increased expression of CDH1 protein]; Imatinib Mesylate promotes the reaction [Niclosamide results in decreased expression of CTNNB1 protein]; Niclosamide inhibits the reaction [CTNNB1 protein binds to CTNNBIP1 protein]; Niclosamide inhibits the reaction [Lithium Chloride affects the localization of CTNNB1 protein]; Niclosamide inhibits the reaction [TNF protein affects the localization of CTNNB1 protein]; Niclosamide inhibits the reaction [WNT3A protein affects the localization of CTNNB1 protein]; Niclosamide inhibits the reaction [WNT3A protein results in increased stability of CTNNB1 protein]; Niclosamide promotes the reaction [Imatinib Mesylate results in decreased expression of CTNNB1 protein]; Niclosamide results in decreased expression of and results in increased phosphorylation of CTNNB1 protein |
CTD |
PMID:19772353 PMID:21531761 PMID:22576131 PMID:24534281 PMID:24552774 PMID:24736023 PMID:25174399 PMID:26964897 PMID:27226553 PMID:27492973 PMID:28284560 PMID:30143678 PMID:32961231 PMID:35115509 PMID:36318118 More...
|
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctnnbip1 |
catenin, beta-interacting protein 1 |
multiple interactions increases expression |
ISO |
Niclosamide inhibits the reaction [CTNNB1 protein binds to CTNNBIP1 protein] Niclosamide results in increased expression of CTNNBIP1 mRNA |
CTD |
PMID:24534281 PMID:36318118 |
|
NCBI chr 5:159,961,961...160,010,942
Ensembl chr 5:159,961,928...160,010,939
|
|
G |
Ctsc |
cathepsin C |
decreases expression |
ISO |
Niclosamide results in decreased expression of CTSC protein |
CTD |
PMID:29480568 |
|
NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387
|
|
G |
Ctsd |
cathepsin D |
decreases expression |
ISO |
Niclosamide results in decreased expression of CTSD protein |
CTD |
PMID:29480568 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA] |
CTD |
PMID:26792726 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CXCL12 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcr5 |
C-X-C motif chemokine receptor 5 |
multiple interactions |
ISO |
Niclosamide affects the reaction [FAS protein mutant form affects the expression of CXCR5 mRNA] |
CTD |
PMID:33632240 |
|
NCBI chr 8:44,842,098...44,858,425
Ensembl chr 8:44,843,413...44,857,893
|
|
G |
Cyb561 |
cytochrome b-561 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CYB561 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:90,878,052...90,888,734
Ensembl chr10:90,878,054...90,884,787
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression |
ISO |
Niclosamide results in increased expression of CYCS protein |
CTD |
PMID:26703449 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity |
ISO |
Niclosamide results in increased activity of CYP1A1 protein |
CTD |
PMID:12451431 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity increases expression |
ISO |
Niclosamide results in decreased activity of CYP1A2 protein Niclosamide results in increased expression of CYP1A2 mRNA |
CTD |
PMID:11124226 PMID:28284560 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
increases expression |
ISO |
Niclosamide results in increased expression of CYP27A1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
Niclosamide results in decreased activity of CYP2D6 protein |
CTD |
PMID:11124226 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp39a1 |
cytochrome P450, family 39, subfamily a, polypeptide 1 |
increases expression |
ISO |
Niclosamide results in increased expression of CYP39A1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:17,230,455...17,306,775
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Niclosamide results in decreased activity of CYP3A4 protein |
CTD |
PMID:11124226 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dact3 |
dishevelled-binding antagonist of beta-catenin 3 |
increases expression |
ISO |
Niclosamide results in increased expression of DACT3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:77,546,900...77,558,631
Ensembl chr 1:77,546,900...77,558,630
|
|
G |
Dbp |
D-box binding PAR bZIP transcription factor |
increases expression |
ISO |
Niclosamide results in increased expression of DBP mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745
|
|
G |
Ddah2 |
DDAH family member 2, ADMA-independent |
increases expression |
ISO |
Niclosamide results in increased expression of DDAH2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr20:3,761,460...3,764,718
Ensembl chr20:3,761,465...3,764,511
|
|
G |
Ddias |
DNA damage-induced apoptosis suppressor |
decreases expression |
ISO |
Niclosamide results in decreased expression of DDIAS mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:146,906,150...146,930,462
Ensembl chr 1:146,906,154...146,930,462
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
Niclosamide results in increased expression of DDIT3 mRNA; Niclosamide results in increased expression of DDIT3 protein ATF3 protein affects the reaction [Niclosamide results in increased expression of DDIT3 mRNA] |
CTD |
PMID:26917416 PMID:36318118 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
ISO |
Niclosamide results in increased expression of DDIT4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
increases expression |
ISO |
Niclosamide results in increased expression of DDR1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468
|
|
G |
Decr1 |
2,4-dienoyl-CoA reductase 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of DECR1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 5:29,411,172...29,439,054
Ensembl chr 5:29,411,172...29,439,018
|
|
G |
Dgcr8 |
DGCR8 microprocessor complex subunit |
decreases expression |
ISO |
Niclosamide results in decreased expression of DGCR8 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr11:82,704,673...82,737,251
Ensembl chr11:82,704,729...82,737,242
|
|
G |
Dgkb |
diacylglycerol kinase, beta |
increases expression |
ISO |
Niclosamide results in increased expression of DGKB mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 6:54,640,948...55,397,210
Ensembl chr 6:54,641,614...55,397,043
|
|
G |
Dhfr |
dihydrofolate reductase |
decreases expression |
ISO |
Niclosamide results in decreased expression of DHFR mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
|
|
G |
Dhrs3 |
dehydrogenase/reductase 3 |
increases expression |
ISO |
Niclosamide results in increased expression of DHRS3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:156,747,939...156,782,420
Ensembl chr 5:156,747,962...156,782,417
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of DKK1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
increases expression |
ISO |
Niclosamide results in increased expression of DLG4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153
|
|
G |
Dmac2l |
distal membrane arm assembly component 2 like |
decreases expression |
ISO |
Niclosamide results in decreased expression of DMAC2L mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 6:88,205,580...88,223,934
Ensembl chr 6:88,205,700...88,223,933
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of DNAJA1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967
|
|
G |
Dnaja4 |
DnaJ heat shock protein family (Hsp40) member A4 |
decreases expression |
ISO |
Niclosamide results in decreased expression of DNAJA4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 8:55,085,246...55,102,715
Ensembl chr 8:55,085,464...55,101,207
|
|
G |
Dnajc22 |
DnaJ heat shock protein family (Hsp40) member C22 |
increases expression |
ISO |
Niclosamide results in increased expression of DNAJC22 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 7:130,257,504...130,262,880
Ensembl chr 7:130,257,851...130,263,230
|
|
G |
Dnajc9 |
DnaJ heat shock protein family (Hsp40) member C9 |
decreases expression |
ISO |
Niclosamide results in decreased expression of DNAJC9 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118
|
|
G |
Dock5 |
dedicator of cytokinesis 5 |
decreases expression |
ISO |
Niclosamide results in decreased expression of DOCK5 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr15:41,979,728...42,158,733
Ensembl chr15:41,979,729...42,158,649
|
|
G |
Dqx1 |
DEAQ box RNA-dependent ATPase 1 |
increases expression |
ISO |
Niclosamide results in increased expression of DQX1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 4:115,563,497...115,572,598
Ensembl chr 4:115,563,752...115,572,590
|
|
G |
Drd4 |
dopamine receptor D4 |
increases expression |
ISO |
Niclosamide results in increased expression of DRD4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553
|
|
G |
Dscc1 |
DNA replication and sister chromatid cohesion 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in increased expression of DSCC1 mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212
|
|
G |
Dtl |
denticleless E3 ubiquitin protein ligase homolog |
decreases expression |
ISO |
Niclosamide results in decreased expression of DTL mRNA |
CTD |
PMID:36318118 |
|
NCBI chr13:103,115,810...103,155,029
Ensembl chr13:103,117,186...103,154,890
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
increases expression |
ISO |
Niclosamide results in increased expression of DUSP4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
|
|
G |
Dusp8 |
dual specificity phosphatase 8 |
increases expression |
ISO |
Niclosamide results in increased expression of DUSP8 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:197,167,392...197,184,285
Ensembl chr 1:197,169,422...197,182,921
|
|
G |
Dusp9 |
dual specificity phosphatase 9 |
increases expression |
ISO |
Niclosamide results in increased expression of DUSP9 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr X:151,351,897...151,355,822
Ensembl chr X:151,351,897...151,355,821
|
|
G |
Dvl1 |
dishevelled segment polarity protein 1 |
increases expression |
ISO |
Niclosamide results in increased expression of DVL1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 5:166,456,989...166,468,733
Ensembl chr 5:166,456,686...166,468,664
|
|
G |
Dvl2 |
dishevelled segment polarity protein 2 |
decreases expression multiple interactions |
ISO EXP |
Niclosamide results in decreased expression of DVL2 protein Niclosamide inhibits the reaction [Thioacetamide results in increased expression of DVL2 mRNA]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of DVL2 mRNA]] |
CTD |
PMID:19772353 PMID:21531761 PMID:30143678 PMID:32961231 |
|
NCBI chr10:54,723,356...54,732,823
Ensembl chr10:54,723,411...54,732,820
|
|
G |
Dvl3 |
dishevelled segment polarity protein 3 |
increases expression |
ISO |
Niclosamide results in increased expression of DVL3 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr11:80,365,446...80,382,641
Ensembl chr11:80,366,117...80,382,462
|
|
G |
Dyrk1b |
dual specificity tyrosine phosphorylation regulated kinase 1B |
increases expression |
ISO |
Niclosamide results in increased expression of DYRK1B mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:83,479,168...83,497,011
Ensembl chr 1:83,479,147...83,487,169
|
|
G |
E2f1 |
E2F transcription factor 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of E2F1 mRNA |
CTD |
PMID:29843133 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f2 |
E2F transcription factor 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of E2F2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217
|
|
G |
E2f7 |
E2F transcription factor 7 |
decreases expression |
ISO |
Niclosamide results in decreased expression of E2F7 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 7:46,150,533...46,192,739
Ensembl chr 7:46,151,293...46,192,734
|
|
G |
E2f8 |
E2F transcription factor 8 |
decreases expression |
ISO |
Niclosamide results in decreased expression of E2F8 mRNA |
CTD |
PMID:28284560 PMID:36318118 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Eaf2 |
ELL associated factor 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of EAF2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr11:63,960,200...64,004,610
Ensembl chr11:63,960,200...64,004,610
|
|
G |
Ebf1 |
EBF transcription factor 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of EBF1 mRNA |
CTD |
PMID:27226553 |
|
NCBI chr10:29,095,858...29,489,142
Ensembl chr10:29,099,933...29,487,665
|
|
G |
Ebf4 |
EBF family member 4 |
increases expression |
ISO |
Niclosamide results in increased expression of EBF4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 3:117,498,186...117,566,566
Ensembl chr 3:117,498,319...117,566,566
|
|
G |
Echdc1 |
ethylmalonyl-CoA decarboxylase 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ECHDC1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 1:28,476,354...28,507,173
Ensembl chr 1:28,476,200...28,507,319
|
|
G |
Echdc2 |
enoyl CoA hydratase domain containing 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ECHDC2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:122,915,874...122,934,860
Ensembl chr 5:122,916,134...122,934,859
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ECHS1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Efna1 |
ephrin A1 |
increases expression |
ISO |
Niclosamide results in increased expression of EFNA1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866
|
|
G |
Efna3 |
ephrin A3 |
increases expression |
ISO |
Niclosamide results in increased expression of EFNA3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 2:174,729,192...174,738,111
Ensembl chr 2:174,729,764...174,738,736
|
|
G |
Efnb3 |
ephrin B3 |
increases expression |
ISO |
Niclosamide results in increased expression of EFNB3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:54,274,506...54,281,951
Ensembl chr10:54,274,506...54,280,471
|
|
G |
Egf |
epidermal growth factor |
decreases expression multiple interactions |
ISO |
Niclosamide results in decreased expression of EGF mRNA; Niclosamide results in decreased expression of EGF protein [3,4,5,3',4'-pentachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Atrazine co-treated with Niclosamide co-treated with nonachlor co-treated with bisphenol S] inhibits the reaction [EGF protein binds to EGFR protein]; [3,4,5,3',4'-pentachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Atrazine co-treated with Niclosamide co-treated with nonachlor co-treated with bisphenol S] inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Niclosamide inhibits the reaction [EGF protein binds to EGFR protein]; Niclosamide inhibits the reaction [EGF protein results in increased expression of HIF1A mRNA]; Niclosamide inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:30779072 PMID:38185387 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression multiple interactions decreases phosphorylation |
ISO |
Niclosamide analog results in decreased expression of EGFR protein; Niclosamide results in decreased expression of EGFR mRNA; Niclosamide results in decreased expression of EGFR protein [3,4,5,3',4'-pentachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Atrazine co-treated with Niclosamide co-treated with nonachlor co-treated with bisphenol S] inhibits the reaction [EGF protein binds to EGFR protein]; [3,4,5,3',4'-pentachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Atrazine co-treated with Niclosamide co-treated with nonachlor co-treated with bisphenol S] inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Niclosamide inhibits the reaction [EGF protein binds to EGFR protein] Niclosamide results in decreased phosphorylation of EGFR protein |
CTD |
PMID:28284560 PMID:28426875 PMID:30779072 PMID:38185387 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression decreases expression |
ISO |
Niclosamide results in increased expression of EGR1 mRNA Niclosamide results in decreased expression of EGR1 mRNA |
CTD |
PMID:28284560 PMID:36318118 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases expression multiple interactions |
ISO |
Niclosamide results in increased expression of EIF2AK3 mRNA ATF3 protein affects the reaction [Niclosamide results in increased expression of EIF2AK3 mRNA]; Niclosamide results in increased expression of and results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:26917416 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation |
ISO |
Niclosamide results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:26917416 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eif4a2 |
eukaryotic translation initiation factor 4A2 |
increases expression |
ISO |
Niclosamide results in increased expression of EIF4A2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr11:77,764,126...77,770,810
Ensembl chr11:77,764,124...77,770,781
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
Niclosamide promotes the reaction [EIF4E protein binds to EIF4EBP1 protein] |
CTD |
PMID:19771169 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
decreases expression multiple interactions decreases phosphorylation |
ISO |
Niclosamide analog results in decreased expression of EIF4EBP1 protein modified form; Niclosamide results in decreased expression of EIF4EBP1 protein modified form Niclosamide inhibits the reaction [MTOR protein results in increased phosphorylation of EIF4EBP1 protein]; Niclosamide promotes the reaction [EIF4E protein binds to EIF4EBP1 protein] Niclosamide results in decreased phosphorylation of EIF4EBP1 protein |
CTD |
PMID:19771169 PMID:28284560 PMID:30258081 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Elf1 |
E74 like ETS transcription factor 1 |
increases expression |
ISO |
Niclosamide results in increased expression of ELF1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr15:54,890,644...54,986,721
Ensembl chr15:54,865,616...54,986,699
|
|
G |
Elfn1 |
extracellular leucine-rich repeat and fibronectin type III domain containing 1 |
increases expression |
ISO |
Niclosamide results in increased expression of ELFN1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr12:14,660,049...14,725,709
Ensembl chr12:14,660,083...14,724,580
|
|
G |
Eml2 |
EMAP like 2 |
increases expression |
ISO |
Niclosamide results in increased expression of EML2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:78,827,595...78,859,342
Ensembl chr 1:78,828,080...78,859,341
|
|
G |
Endod1 |
endonuclease domain containing 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in increased expression of ENDOD1 mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr 8:11,209,113...11,238,507
Ensembl chr 8:11,211,110...11,238,892
|
|
G |
Eng |
endoglin |
increases expression |
ISO |
Niclosamide results in increased expression of ENG mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230
|
|
G |
Eno2 |
enolase 2 |
increases expression |
ISO |
Niclosamide results in increased expression of ENO2 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Eno3 |
enolase 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ENO3 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921
|
|
G |
Ep300 |
E1A binding protein p300 |
increases expression |
ISO |
Niclosamide results in increased expression of EP300 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Oxygen deficiency results in increased expression of EPAS1 protein] |
CTD |
PMID:36318118 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Epha8 |
Eph receptor A8 |
increases expression |
ISO |
Niclosamide results in increased expression of EPHA8 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:149,166,107...149,193,515
Ensembl chr 5:149,166,697...149,193,399
|
|
G |
Eps8l3 |
EPS8 like 3 |
increases expression |
ISO |
Niclosamide results in increased expression of EPS8L3 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 2:195,514,692...195,528,085
Ensembl chr 2:195,514,692...195,528,085
|
|
G |
Ethe1 |
ETHE1, persulfide dioxygenase |
increases expression |
ISO |
Niclosamide results in increased expression of ETHE1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:80,184,037...80,199,092
Ensembl chr 1:80,183,894...80,199,052
|
|
G |
Eva1b |
eva-1 homolog B |
increases expression |
ISO |
Niclosamide results in increased expression of EVA1B mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:138,427,088...138,429,602
Ensembl chr 5:138,427,151...138,432,433
|
|
G |
Exo5 |
exonuclease 5 |
decreases expression |
ISO |
Niclosamide results in decreased expression of EXO5 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:134,494,440...134,497,757
Ensembl chr 5:134,493,829...134,497,772
|
|
G |
Exog |
exo/endonuclease G |
decreases expression |
ISO |
Niclosamide results in decreased expression of EXOG mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 8:119,184,974...119,204,819
Ensembl chr 8:119,185,136...119,204,672
|
|
G |
F10 |
coagulation factor X |
increases expression |
ISO |
Niclosamide results in increased expression of F10 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F12 |
coagulation factor XII |
increases expression |
ISO |
Niclosamide results in increased expression of F12 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr17:9,207,683...9,215,530
Ensembl chr17:9,207,683...9,215,530
|
|
G |
Fam131c |
family with sequence similarity 131, member C |
increases expression |
ISO |
Niclosamide results in increased expression of FAM131C mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:153,674,459...153,690,791
Ensembl chr 5:153,671,772...153,690,800
|
|
G |
Fam135b |
family with sequence similarity 135, member B |
increases expression |
ISO |
Niclosamide results in increased expression of FAM135B mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 7:103,380,981...103,649,802
Ensembl chr 7:103,386,915...103,649,708
|
|
G |
Fam13b |
family with sequence similarity 13, member B |
decreases expression |
ISO |
Niclosamide results in decreased expression of FAM13B mRNA |
CTD |
PMID:36318118 |
|
NCBI chr18:26,040,285...26,107,112
Ensembl chr18:26,040,285...26,106,587
|
|
G |
Fam221a |
family with sequence similarity 221, member A |
increases expression |
ISO |
Niclosamide results in increased expression of FAM221A mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 4:78,337,296...78,358,918
Ensembl chr 4:78,337,296...78,358,909
|
|
G |
Fam43a |
family with sequence similarity 43, member A |
increases expression |
ISO |
Niclosamide results in increased expression of FAM43A mRNA |
CTD |
PMID:36318118 |
|
NCBI chr11:70,128,253...70,131,401
Ensembl chr11:70,128,253...70,131,401
|
|
G |
Fam43b |
family with sequence similarity 43, member B |
increases expression |
ISO |
Niclosamide results in increased expression of FAM43B mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:150,610,656...150,613,054
Ensembl chr 5:150,611,609...150,612,601
|
|
G |
Fam83d |
family with sequence similarity 83, member D |
decreases expression |
ISO |
Niclosamide results in decreased expression of FAM83D mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 3:147,421,941...147,441,211
Ensembl chr 3:147,421,908...147,441,192
|
|
G |
Fancb |
FA complementation group B |
decreases expression |
ISO |
Niclosamide results in decreased expression of FANCB mRNA |
CTD |
PMID:36318118 |
|
NCBI chr X:29,403,771...29,420,484
Ensembl chr X:29,403,771...29,420,192
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO EXP |
Niclosamide affects the reaction [FAS protein mutant form affects the expression of BCL6 mRNA]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of BCL6 protein]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of CXCR5 mRNA]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of IL21 protein]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of IL6 protein]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of PRDM1 mRNA]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of TCF7 protein]; Niclosamide affects the reaction [FAS protein mutant form affects the phosphorylation of STAT3 protein]; Niclosamide inhibits the reaction [Doxorubicin results in increased expression of FAS mRNA] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of FAS mRNA] |
CTD |
PMID:28318631 PMID:33632240 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fastkd3 |
FAST kinase domains 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of FASTKD3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:34,858,342...34,866,988
Ensembl chr 1:34,858,219...34,866,973
|
|
G |
Fbxo2 |
F-box protein 2 |
increases expression |
ISO |
Niclosamide results in increased expression of FBXO2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:158,592,926...158,598,355
Ensembl chr 5:158,592,925...158,598,355
|
|
G |
Fbxo48 |
F-box protein 48 |
increases expression |
ISO |
Niclosamide results in increased expression of FBXO48 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr14:91,380,857...91,382,314
Ensembl chr14:91,380,857...91,382,314
|
|
G |
Fcho1 |
FCH and mu domain containing endocytic adaptor 1 |
increases expression |
ISO |
Niclosamide results in increased expression of FCHO1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr16:18,413,452...18,430,795
Ensembl chr16:18,413,363...18,435,104
|
|
G |
Fcrlb |
Fc receptor-like B |
increases expression |
ISO |
Niclosamide results in increased expression of FCRLB mRNA |
CTD |
PMID:36318118 |
|
NCBI chr13:83,148,685...83,157,157
Ensembl chr13:83,149,751...83,155,957
|
|
G |
Fen1 |
flap structure-specific endonuclease 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of FEN1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003
|
|
G |
Fgd1 |
FYVE, RhoGEF and PH domain containing 1 |
increases expression |
ISO |
Niclosamide results in increased expression of FGD1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr X:20,023,746...20,066,734
Ensembl chr X:20,023,746...20,066,566
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of FGF1 mRNA; Niclosamide results in decreased expression of FGF1 protein |
CTD |
PMID:25174399 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
increases expression |
ISO |
Niclosamide results in increased expression of FGF19 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
increases expression |
ISO |
Niclosamide results in increased expression of FGFR4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242
|
|
G |
Fignl1 |
fidgetin-like 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of FIGNL1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr14:86,368,670...86,381,728
Ensembl chr14:86,368,675...86,377,455
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions decreases expression |
ISO |
[Niclosamide co-treated with bicalutamide] results in decreased expression of FKBP5 mRNA Niclosamide results in decreased expression of FKBP5 mRNA |
CTD |
PMID:28500234 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Flrt3 |
fibronectin leucine rich transmembrane protein 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of FLRT3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 3:127,994,491...128,008,137
Ensembl chr 3:127,994,226...128,007,841
|
|
G |
Fmn1 |
formin 1 |
increases expression |
ISO |
Niclosamide results in increased expression of FMN1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 3:100,101,103...100,485,652
Ensembl chr 3:100,134,549...100,479,220
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of FN1 protein] HIPK2 protein inhibits the reaction [Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA] |
CTD |
PMID:28318631 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fndc10 |
fibronectin type III domain containing 10 |
increases expression |
ISO |
Niclosamide results in increased expression of FNDC10 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:166,299,587...166,311,477
Ensembl chr 5:166,300,122...166,310,326
|
|
G |
Fndc4 |
fibronectin type III domain containing 4 |
increases expression |
ISO |
Niclosamide results in increased expression of FNDC4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 6:25,077,155...25,080,812
Ensembl chr 6:25,077,349...25,080,675
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of FOS mRNA] Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein] |
CTD |
PMID:26792726 PMID:28824321 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Niclosamide results in increased expression of FOSB mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
Niclosamide results in increased expression of FOSL1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Foxl1 |
forkhead box L1 |
increases expression |
ISO |
Niclosamide results in increased expression of FOXL1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr19:49,197,269...49,200,682
Ensembl chr19:49,197,400...49,198,425
|
|
G |
Foxm1 |
forkhead box M1 |
multiple interactions decreases expression |
ISO |
Imatinib Mesylate promotes the reaction [Niclosamide results in decreased expression of FOXM1 protein]; Niclosamide inhibits the reaction [TNF protein affects the localization of FOXM1 protein]; Niclosamide promotes the reaction [Imatinib Mesylate results in decreased expression of FOXM1 protein] |
CTD |
PMID:27492973 |
|
NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Foxo4 |
forkhead box O4 |
increases expression |
ISO |
Niclosamide results in increased expression of FOXO4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr X:66,385,241...66,392,115
Ensembl chr X:66,385,558...66,392,115
|
|
G |
Foxo6 |
forkhead box O6 |
increases expression |
ISO |
Niclosamide results in increased expression of FOXO6 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:133,856,087...133,876,387
Ensembl chr 5:133,856,072...133,876,573
|
|
G |
Frat2 |
FRAT regulator of WNT signaling pathway 2 |
increases expression |
ISO |
Niclosamide results in increased expression of FRAT2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:240,654,120...240,656,449
Ensembl chr 1:240,654,137...240,656,517
|
|
G |
Frzb |
frizzled-related protein |
increases expression |
ISO |
Niclosamide results in increased expression of FRZB mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 3:65,332,274...65,365,208
Ensembl chr 3:65,332,277...65,365,208
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of FSCN1 mRNA] |
CTD |
PMID:29733962 |
|
NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211
|
|
G |
Fstl3 |
follistatin like 3 |
increases expression |
ISO |
Niclosamide results in increased expression of FSTL3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 7:9,923,574...9,929,223
Ensembl chr 7:9,923,576...9,939,639
|
|
G |
Fzd1 |
frizzled class receptor 1 |
affects localization |
ISO |
Niclosamide affects the localization of FZD1 protein |
CTD |
PMID:19772353 |
|
NCBI chr 4:29,310,303...29,314,701
Ensembl chr 4:29,310,091...29,312,643 Ensembl chr 4:29,310,091...29,312,643
|
|
G |
Fzd2 |
frizzled class receptor 2 |
decreases expression increases expression |
ISO |
Niclosamide results in decreased expression of FZD2 mRNA Niclosamide results in increased expression of FZD2 mRNA |
CTD |
PMID:22576131 PMID:36318118 |
|
NCBI chr10:87,561,866...87,563,776
Ensembl chr10:87,561,326...87,565,334
|
|
G |
Fzd5 |
frizzled class receptor 5 |
increases expression |
ISO |
Niclosamide results in increased expression of FZD5 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 9:66,113,096...66,120,276
Ensembl chr 9:66,113,112...66,121,457
|
|
G |
Fzd9 |
frizzled class receptor 9 |
decreases expression |
ISO |
Niclosamide results in decreased expression of FZD9 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr12:21,427,084...21,429,398
Ensembl chr12:21,427,084...21,429,398
|
|
G |
G4 |
G4 protein |
affects expression |
ISO |
Niclosamide affects the expression of C6ORF47 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr20:3,693,691...3,696,194
Ensembl chr20:3,693,649...3,696,088
|
|
G |
Gab2 |
GRB2-associated binding protein 2 |
increases expression |
ISO |
Niclosamide results in increased expression of GAB2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:151,429,844...151,625,708
Ensembl chr 1:151,429,695...151,625,031
|
|
G |
Gabarapl1 |
GABA type A receptor associated protein like 1 |
increases expression |
ISO |
Niclosamide results in increased expression of GABARAPL1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 4:162,980,309...162,989,452
Ensembl chr 4:162,980,249...162,989,450
|
|
G |
Gabra4 |
gamma-aminobutyric acid type A receptor subunit alpha 4 |
increases expression |
ISO |
Niclosamide results in increased expression of GABRA4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr14:36,590,782...36,667,724
Ensembl chr14:36,590,782...36,665,844
|
|
G |
Gabrb1 |
gamma-aminobutyric acid type A receptor subunit beta1 |
increases expression |
ISO |
Niclosamide results in increased expression of GABRB1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr14:36,068,725...36,548,946
Ensembl chr14:36,080,393...36,548,948
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
increases expression |
ISO |
Niclosamide results in increased expression of GADD45B mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Garin1a |
golgi associated RAB2 interactor 1A |
increases expression |
ISO |
Niclosamide results in increased expression of GARIN1A mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 4:57,880,019...57,890,824
Ensembl chr 4:57,880,019...57,890,820
|
|
G |
Gata5 |
GATA binding protein 5 |
increases expression |
ISO |
Niclosamide results in increased expression of GATA5 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 3:167,418,563...167,426,751
Ensembl chr 3:167,418,565...167,426,751
|
|
G |
Gcg |
glucagon |
multiple interactions |
EXP |
Niclosamide inhibits the reaction [GCG protein results in increased abundance of Cyclic AMP]; Niclosamide inhibits the reaction [GCG protein results in increased expression of CCND1 mRNA]; Niclosamide inhibits the reaction [GCG protein results in increased expression of CCND1 protein]; Niclosamide inhibits the reaction [GCG protein results in increased expression of MYC mRNA]; Niclosamide inhibits the reaction [GCG protein results in increased phosphorylation of CTNNB1 protein] |
CTD |
PMID:26964897 |
|
NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
decreases expression |
ISO |
Niclosamide results in decreased expression of GCLM mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
Niclosamide results in increased expression of GDF15 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gdpd5 |
glycerophosphodiester phosphodiesterase domain containing 5 |
increases expression |
ISO |
Niclosamide results in increased expression of GDPD5 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:153,679,718...153,761,452
Ensembl chr 1:153,679,718...153,761,446
|
|
G |
Gdpgp1 |
GDP-D-glucose phosphorylase 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of GDPGP1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:134,184,119...134,193,281
Ensembl chr 1:134,183,696...134,219,783
|
|
G |
Gfap |
glial fibrillary acidic protein |
decreases expression |
ISO |
Niclosamide results in decreased expression of GFAP protein |
CTD |
PMID:34118929 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gid4 |
GID complex subunit 4 |
increases expression |
ISO |
Niclosamide results in increased expression of GID4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:45,221,556...45,247,627
Ensembl chr10:45,245,754...45,247,621 Ensembl chr10:45,245,754...45,247,621
|
|
G |
Gins1 |
GINS complex subunit 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of GINS1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 3:139,724,513...139,745,930
Ensembl chr 3:139,724,490...139,745,936
|
|
G |
Gins2 |
GINS complex subunit 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of GINS2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr19:48,626,770...48,639,523
Ensembl chr19:48,626,770...48,639,339
|
|
G |
Gins3 |
GINS complex subunit 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of GINS3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr19:9,420,085...9,428,621
Ensembl chr19:9,420,086...9,428,687
|
|
G |
Gins4 |
GINS complex subunit 4 |
decreases expression |
ISO |
Niclosamide results in decreased expression of GINS4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr16:68,787,572...68,799,938
Ensembl chr16:68,767,339...68,802,273
|
|
G |
Glb1l3 |
galactosidase, beta 1-like 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of GLB1L3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 8:25,179,165...25,220,904
Ensembl chr 8:25,179,165...25,220,904
|
|
G |
Glis1 |
GLIS family zinc finger 1 |
increases expression |
ISO |
Niclosamide results in increased expression of GLIS1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:122,222,155...122,412,141
Ensembl chr 5:122,222,128...122,412,141
|
|
G |
Glis2 |
GLIS family zinc finger 2 |
increases expression |
ISO |
Niclosamide results in increased expression of GLIS2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:10,951,157...10,978,524
Ensembl chr10:10,951,371...10,971,578
|
|
G |
Gng7 |
G protein subunit gamma 7 |
increases expression |
ISO |
Niclosamide results in increased expression of GNG7 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 7:8,697,458...8,761,239
Ensembl chr 7:8,697,521...8,761,240
|
|
G |
Golga2 |
golgin A2 |
increases expression |
ISO |
Niclosamide results in increased expression of GOLGA2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 3:15,583,862...15,604,279
Ensembl chr 3:15,584,039...15,604,279
|
|
G |
Gosr2 |
golgi SNAP receptor complex member 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of GOSR2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:88,585,291...88,605,642
Ensembl chr10:88,586,299...88,605,625
|
|
G |
Got2 |
glutamic-oxaloacetic transaminase 2 |
increases expression |
ISO |
Niclosamide results in increased expression of GOT2 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr19:9,174,304...9,199,995
Ensembl chr19:9,174,311...9,199,994
|
|
G |
Gp1bb |
glycoprotein Ib platelet subunit beta |
increases expression |
ISO |
Niclosamide results in increased expression of GP1BB mRNA |
CTD |
PMID:36318118 |
|
NCBI chr11:82,378,216...82,379,393
Ensembl chr11:82,378,199...82,379,392
|
|
G |
Gpc2 |
glypican 2 |
increases expression |
ISO |
Niclosamide results in increased expression of GPC2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr12:17,277,875...17,284,297
Ensembl chr12:17,277,875...17,284,208
|
|
G |
Gpr153 |
G protein-coupled receptor 153 |
increases expression |
ISO |
Niclosamide results in increased expression of GPR153 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:162,781,587...162,792,975
Ensembl chr 5:162,781,587...162,792,971
|
|
G |
Gpr75 |
G protein-coupled receptor 75 |
decreases expression |
ISO |
Niclosamide results in decreased expression of GPR75 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr14:104,609,542...104,618,885
Ensembl chr14:104,611,089...104,620,370
|
|
G |
Gprc5c |
G protein-coupled receptor, class C, group 5, member C |
increases expression |
ISO |
Niclosamide results in increased expression of GPRC5C mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:99,886,900...99,908,928
Ensembl chr10:99,887,077...99,908,926
|
|
G |
Grem2 |
gremlin 2, DAN family BMP antagonist |
decreases expression |
ISO |
Niclosamide results in decreased expression of GREM2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr13:86,778,543...86,871,509
Ensembl chr13:86,778,500...86,871,615
|
|
G |
Grik5 |
glutamate ionotropic receptor kainate type subunit 5 |
increases expression |
ISO |
Niclosamide results in increased expression of GRIK5 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:80,605,878...80,667,896
Ensembl chr 1:80,605,892...80,667,125
|
|
G |
Grin2d |
glutamate ionotropic receptor NMDA type subunit 2D |
increases expression |
ISO |
Niclosamide results in increased expression of GRIN2D mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:96,306,871...96,346,994
Ensembl chr 1:96,308,365...96,344,793
|
|
G |
Grip2 |
glutamate receptor interacting protein 2 |
increases expression |
ISO |
Niclosamide results in increased expression of GRIP2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 4:124,271,456...124,356,538
Ensembl chr 4:124,271,456...124,321,268
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases expression increases phosphorylation decreases phosphorylation |
ISO |
Niclosamide results in decreased expression of GSK3B mRNA Niclosamide results in increased phosphorylation of GSK3B protein Niclosamide results in decreased phosphorylation of GSK3B protein |
CTD |
PMID:22576131 PMID:30143678 PMID:35115509 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gstt2 |
glutathione S-transferase theta 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of GSTT2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr20:12,819,617...12,823,288
Ensembl chr20:12,819,170...12,823,288
|
|
G |
Gtf2h4 |
general transcription factor 2H subunit 4 |
decreases expression increases expression |
ISO |
Niclosamide results in decreased expression of GTF2H4 mRNA Niclosamide results in increased expression of GTF2H4 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr20:3,071,328...3,076,990
Ensembl chr20:3,071,328...3,076,984
|
|
G |
Gtse1 |
G-2 and S-phase expressed 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of GTSE1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 7:116,949,997...116,966,826
Ensembl chr 7:116,950,053...116,966,806
|
|
G |
Gxylt2 |
glucoside xylosyltransferase 2 |
increases expression |
ISO |
Niclosamide results in increased expression of GXYLT2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 4:133,347,230...133,449,708
Ensembl chr 4:133,347,499...133,449,454
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
decreases expression |
ISO |
Niclosamide results in decreased expression of HADH mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
decreases expression increases expression |
ISO |
Niclosamide results in decreased expression of HAMP mRNA Niclosamide results in increased expression of HAMP mRNA |
CTD |
PMID:25633564 PMID:28284560 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hbp1 |
HMG-box transcription factor 1 |
multiple interactions increases expression |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of HBP1 mRNA] Niclosamide results in increased expression of HBP1 mRNA |
CTD |
PMID:27542212 PMID:36318118 |
|
NCBI chr 6:48,529,633...48,555,775
Ensembl chr 6:48,529,372...48,555,787
|
|
G |
Hdac5 |
histone deacetylase 5 |
increases expression |
ISO |
Niclosamide results in increased expression of HDAC5 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235
|
|
G |
Helz2 |
helicase with zinc finger 2 |
increases expression |
ISO |
Niclosamide results in increased expression of HELZ2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 3:168,338,813...168,353,219
Ensembl chr 3:168,338,813...168,353,159
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
decreases expression multiple interactions |
ISO EXP |
Niclosamide results in decreased expression of HES1 protein Niclosamide inhibits the reaction [Doxorubicin results in increased expression of HES1 mRNA] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HES1 mRNA]; Niclosamide inhibits the reaction [Thioacetamide results in increased expression of HES1 mRNA]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of HES1 mRNA]] |
CTD |
PMID:19160421 PMID:28318631 PMID:32961231 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hey1 |
hes-related family bHLH transcription factor with YRPW motif 1 |
multiple interactions |
ISO EXP |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of HEY1 mRNA] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HEY1 mRNA] Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of HEY1 mRNA] |
CTD |
PMID:27542212 PMID:28318631 |
|
NCBI chr 2:93,096,605...93,100,316
Ensembl chr 2:93,095,498...93,100,312
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
multiple interactions increases expression |
EXP ISO |
Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HEY2 mRNA] Niclosamide inhibits the reaction [Doxorubicin results in increased expression of HEY2 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Niclosamide results in increased expression of HEY2 mRNA] |
CTD |
PMID:19160421 PMID:28318631 |
|
NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218
|
|
G |
Hhipl1 |
HHIP-like 1 |
increases expression |
ISO |
Niclosamide results in increased expression of HHIPL1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 6:127,219,616...127,243,839
Ensembl chr 6:127,220,014...127,242,564
|
|
G |
Hid1 |
HID1 domain containing |
increases expression |
ISO |
Niclosamide results in increased expression of HID1 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr10:100,589,555...100,610,050
Ensembl chr10:100,589,555...100,610,041
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases expression multiple interactions |
ISO |
Niclosamide results in decreased expression of HIF1A mRNA; Niclosamide results in decreased expression of HIF1A protein Niclosamide inhibits the reaction [EGF protein results in increased expression of HIF1A mRNA]; Niclosamide inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein] |
CTD |
PMID:30779072 PMID:36318118 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hipk2 |
homeodomain interacting protein kinase 2 |
multiple interactions |
ISO EXP |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of HIPK2 mRNA]; Niclosamide inhibits the reaction [Doxorubicin results in increased expression of HIPK2 protein] HIPK2 protein inhibits the reaction [Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]]; HIPK2 protein inhibits the reaction [Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]]; HIPK2 protein inhibits the reaction [Niclosamide inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]]; Niclosamide inhibits the reaction [TGFB1 protein promotes the reaction [SMAD3 protein binds to HIPK2 promoter]]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HIPK2 protein] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HIPK2 mRNA]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HIPK2 protein] |
CTD |
PMID:28318631 |
|
NCBI chr 4:67,439,327...67,619,223
Ensembl chr 4:67,440,501...67,619,223
|
|
G |
Hist1h2bc |
histone cluster 1, H2bc |
increases expression |
ISO |
Niclosamide results in increased expression of H2BC21 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr17:42,692,335...42,696,601
Ensembl chr17:42,694,723...42,696,642
|
|
G |
Hivep2 |
HIVEP zinc finger 2 |
increases expression |
ISO |
Niclosamide results in increased expression of HIVEP2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:8,358,205...8,555,993
Ensembl chr 1:8,359,289...8,555,993
|
|
G |
Hk3 |
hexokinase 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of HK3 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr17:9,596,950...9,614,847
Ensembl chr17:9,599,865...9,614,863
|
|
G |
Hmgcl |
3-hydroxy-3-methylglutaryl-CoA lyase |
increases expression |
ISO |
Niclosamide results in increased expression of HMGCL mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 5:148,178,203...148,192,072
Ensembl chr 5:148,178,252...148,192,068
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
decreases expression |
ISO |
Niclosamide results in decreased expression of HMMR mRNA |
CTD |
PMID:28284560 |
|
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
|
|
G |
Hmx2 |
H6 family homeobox 2 |
increases expression |
ISO |
Niclosamide results in increased expression of HMX2 mRNA |
CTD |
PMID:36318118 |
|
NCBI chr 1:186,319,110...186,326,771
Ensembl chr 1:186,319,110...186,326,771
|
| |